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Non-canonical amino acids are tools for altering the chemical and physical properties of 
proteins, providing a facile strategy to engineer proteins with novel properties, especially 
where canonical amino acid mutagenesis has exhausted nearly all avenues for further 
optimization. Insulin, for example, is one of the most widely studied therapeutic proteins; 
however, non-canonical insulin engineering is a subfield that has been largely unexplored. 
To this end, my thesis research has focused on the use of non-canonical amino acids to 
understand and engineer the biophysical properties of insulin. 
Protein structure and function are sensitive to the smallest of changes; even small 
differences such as a single atom substitution or change in stereo-orientation can cause 
large, unsuspected, and unpredictable global changes. Chapters 2 to 4 describe 
substitutions at the 4th position of proline at position 28 of insulin’s B chain (ProB28) in a 
manner analogous to the structure-activity-relationships that are widely used in medicinal 
chemistry. Canonical mutagenesis at ProB28 has led to the discovery of rapid-acting insulins 
(RAIs): a class of therapeutic insulins with enhanced pharmacokinetic properties. Therefore, 
we chose to incorporate proline analogs with substitutions such as hydroxyl and fluoro 
groups, and different ring compositions to assess their effects on the biophysical properties 
(i.e. stability, dissociation rates and oligomerizations states) of insulin. Chapter 2 describes 
the discovery of a hydroxyinsulin variant with faster hexamer dissociation rates and 
enhanced stability compared to wild-type insulin in vitro. We find crystallographic evidence 
of a novel hydrogen bond in the insulin dimer interface which we hypothesize stabilizes the 
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insulin dimer state. To complement the findings in chapter 2, chapters 3 and 4 detail an 
investigation of the importance of hydrophobic and nonpolar interactions for modulating 
the biophysical properties of insulin.  
Establishing structure-activity-relationships for insulin will create new opportunities for 
further engineering using non-canonical amino acids. In chapter 5, we describe progress 
towards a general, simple screening method to discover new aminoacyl-tRNA synthetases 
for the incorporation of non-canonical amino acids in E. coli. Implementing such a high-
throughput screening system will allow scientists to perform medicinal chemistry on 
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Importance of biological polymers. Life is encoded in biological polymers and is summarized 
by the central dogma of biology: DNA is first transcribed into (messenger) RNA, which is 
then translated into proteins. Often, human diseases arise from changes in the protein’s 
amino acid sequence, which can be caused1 by a genetic mutation at the chromosomal 
level, an error in transcription by the RNA polymerase, or misacylation by an aminoacyl 
tRNA synthetase during translation by the ribosome. The accumulation of mutations within 
a gene and their corresponding structural changes within a protein2,3 can have extreme 
consequences, especially if the protein is involved in an important signaling pathway. For 
example, one of the causes of Alzheimer’s disease4 (AD) has been speculated to be due to 
one mutation (A42T) in the amyloid precursor protein (APP), which renders its downstream 
protein, amyloid-β (Aβ), more prone to form and accumulate fibrillar aggregates. In addition 
to mutations in a protein’s primary structure, absence of critical proteins can also have dire 
consequences. This is highlighted by diabetes mellitus, a chronic pancreatic illness5, which is 
caused by either the body’s inability to produce (Type I) or respond to (Type II) the blood 
glucose regulating protein, insulin. Since many diseases arise due to specific protein 
irregularities, studying and utilizing these complex biological polymers can offer beneficial 
alternative treatment methods.  
Protein therapeutics. One advantage for the clinical use of protein therapeutics over small 
molecule drugs is the specificity of the protein to induce a complex set of functions6. 
Proteins have naturally evolved from the 20 canonical amino acids (cAAs) whose unique 
side-chains participates in determining the structure of the macromolecule, which in turn 
determines its function. Since the accessible sequence space for proteins is near limitless, 
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the potential to create is enormous. No synthetically derived non-proteinaceous molecule 
can replicate a protein’s shape, specificity, and therefore, is able to function at the same 
molecular level. In the field of protein therapeutics, the relationship between structure and 
function is navigated to produce proteins that can replace or improve upon the effects of 
existing (or deficient) cellular functions with the goal of combating illness. If a disease is 
caused by the absence of a protein, then treatment should naturally involve providing the 
patient with an exogenous supply. This was the case with the first therapeutic protein, 
insulin, which was described as an endocrine hormone in the late 19th century7, and to date 
no small-molecule or other alternative has been discovered that can interact with the 
insulin receptor in the presence of glucose in the same way as insulin. Subsequent work led 
to the use of insulin as a life-saving treatment for diabetes nearly thirty years later for which 
Frederick Banting and J. R. R. Macleod were awarded the Nobel prize in 19237. Recombinant 
DNA (recDNA) technology has further facilitated the clinical use of proteins8 and has helped 
the pharmaceutical industry achieve production on relevant scales6. For example, insulin for 
treatment was originally derived solely from bovine or porcine sources; it has since been 
replaced by recombinant insulin, which was approved by the Food and Drug Administration 
(FDA) in 19828. Developing protein therapeutics also allows scientists to take advantage of 
having complete control over primary structure and post-translational modifications. 
Currently there is much interest in using the specificity of proteins to target specific cell 
types (e.g. cancer cells) and deliver a coupled small-molecule9. Ideally, proteins can be 
developed with the desired activity profile, clearance properties, and physical 
characteristics without interfering with other cellular processes and with limited toxicity10. 
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However, there remain several drawbacks: in vivo limitations, such as clearance pathways 
through protease activity, kidney filtration and the production of neutralizing antibodies by 
the body’s immune response11, and in vitro formulation (i.e. long-term stability) 
challenges12. These shortcomings are areas of current research13,14 and the work described 
in this thesis is aimed at demonstrating the potential usefulness of non-canonical amino 
acids (ncAAs) in the field of therapeutic protein engineering. 
Therapeutic protein engineering. Research towards addressing the limitations of 
therapeutic proteins can be broadly categorized into two major strategies11,12: first, 
development of medical devices for greater ease of delivery (e.g. subcutaneous injection 
needles), and second, engineering of the protein itself (e.g. biophysical studies15). The latter 
can be further subdivided into conjugation methods and mutating the protein’s amino acid 
sequence. Conjugation methods have largely been used for the extension of the in vivo half-
life, which is dominated by attaching long polymers11 (e.g. PEGylation) or fatty acids that 
can bind to serum proteins16,17. However, modifying intrinsic protein properties, such as 
stability and solubility18, is not straightforward, especially when coupled with the FDA’s 
requirement that pharmaceutical formulations of therapeutic proteins must maintain 
activity for at least two years19 under proper storage conditions (i.e. 4°C). The functional 
state of proteins is considered metastable20,21 and preventing the undesired (and perhaps 
more stable) aggregated states from forming is a current challenge. This formulation 
problem22,23 is especially difficult considering the propensity of protein aggregation at the 
higher concentrations24 which therapeutic formulations typically require18,25. For example, 
formulating therapeutic insulin involves the addition of zinc ions and phenolic ligands to 
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form its most stable, R6 hexamer state26; this is done so as to prevent the formation of 
insulin fibrils for long-term storage. To obtain desired pharmaceutical properties, there are 
often tradeoffs: e.g. the stable R6 insulin hexamer state is not bioactive, and upon injection 
it requires a lag time to dissociate to its active, monomeric form27. This lag time places on 
the patient the burden of monitoring blood glucose levels and injecting insulin prior to 
meals; it is unsurprising that patient compliance is reported to be a global issue28 among 
diabetics. Thus, important therapeutic proteins such as insulin warrant further investigation 
to engineer a molecule which can better balance its therapeutic value with practical 
concerns regarding its effective use and stability. However, the primary structure of insulin 
is highly conserved, which places limits for the mutational analyses that can be done to 
improve upon its current qualities with the canonical toolbox of amino acids (cAAs). 
Non-canonical amino acids.  New chemical and physical properties can be introduced into 
the proteome through the incorporation29-31 of ncAAs. There are three widely used 
approaches for the incorporation of ncAAs: residue-specific, site-specific, and through in 
vitro or synthetic means. The residue-specific approach circumvents the need for genetic 
manipulation by taking advantage of the promiscuity of the endogenous translational 
machinery.  The use of auxotrophic host strains permits global replacement of a specific 
residue by selective pressure; this is done with the addition of the non-canonical analogue 
into the culture medium in place of the canonical amino acid29. Most site-specific methods 
rely on amber codon suppression and the development of exogenous components for 
protein synthesis; however, this method generally is limited by low protein yields due to the 
termination of translation in response to the stop codon32,33. Recent work has addressed 
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some of the truncation issues through genomically recoded organisms34 (GROs); however, 
the fitness of these engineered strains remains far below that of wild-type strains35 and has, 
thus far, only been demonstrated in Escherichia coli36. The last category for ncAA 
incorporation involves non-cellular means. These include cell-free protein synthesis37 and 
synthetic methods (i.e. chemical acylation of ncAA onto its cognate tRNA31, and peptide 
synthesis) which can be implemented either residue- or site-specifically. 
Residue-specific incorporation of ncAA offers a simple approach to study proteins of 
interest for a variety of applications, such as proteomic analysis, live cell imaging, and 
producing engineered proteins at high yields. The use of ncAAs can largely be described by 
two broad categories: the introduction of reactive moieties allowing for downstream 
enrichment, quantification and identification38, and as probes to engineer and understand 
mechanistic protein behavior: 
Use of ncAA for proteomics. Several reactive ncAA with chemical handles have been 
incorporated into proteins for subsequent modification using reactions such as azide-alkyne 
coupling39-41. This method is termed biorthogonal non-canonical amino acid tagging 
(BONCAT)40; here, the orthogonal moiety is analogous to the use of radiolabeled 
compounds in traditional pulse-chase experiments to distinguish between different 
proteomic states. The reactive handle allows for enrichment of newly synthesized proteins 
to reduce sample complexity prior to mass spectrometry and can be combined with stable 
isotope labeling in cell culture (SILAC) for quantification42,43 (e.g. up- and down-regulated 
proteins in response to a stimulus). BONCAT proteomics has been demonstrated in several 
complex biological systems44-46.  
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Use of ncAA for protein engineering. The relationships among protein sequence, structure, 
and function are central to life, and have been undergoing natural evolution using the 
twenty cAAs. Through the introduction of ncAAs into proteins, the available primary 
sequence space and protein function space can be further expanded beyond the restrictions 
of cAAs. It has been widely demonstrated in the literature that incorporating ncAAs into 
proteins can not only give access to new chemistries, but also affect a protein’s physical 
properties. For example, the thermostability of leucine zipper peptides has been increased 
by the introduction of fluorinated amino acids47. However, regardless of the effects, the 
protein engineer is limited by the cell’s ability to utilize ncAAs. To this end, there is 
significant interest in developing techniques that allow the translational machinery to 
incorporate amino acids with novel side chains. This will be described further in Chapter 5 
where a general, high-throughput method is given for engineering aminoacyl-tRNA 
synthetases to accommodate ncAAs during translation.  
Proline.  The cyclic structure of proline gives its unique traits: puckering of the prolyl-ring 
(exo versus endo conformation), cis-trans isomerization of the amide peptide bond (due to 
the smaller energy difference necessary for cis-trans isomerization48 compared to the other 
cAAs), and constrained dihedral angles. There has been much work done to understand the 
role of critical prolines in proteins; some of this work involves proline analogs49-51 to 
modulate the prolyl ring pucker and its propensity to undergo cis-trans isomerization by 
altering the substituent group on the prolyl ring52. For example, non-canonical prolines 
(ncPro), specifically hydroxy-prolines and fluoroprolines, have contributed to understanding 
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collagen structure and stability53-55, and these approaches have recently been extended to 
globular proteins (i.e. β2-microglobulin50,51,56 and enzymes49,57,58).  
Residue-specific ncPro mutagenesis.  Many of the studies involving the global replacement 
of proline residues have focused on collagen, a fibrous protein that is abundant in 
extracellular matrices. Collagen has a consensus sequence (XaaYaaGly)n, where Xaa is L-
proline, Yaa is typically (4R)-hydroxy-L-proline (Hyp), and n is the number of repeats59. The 
orientation of the hydroxyl group at position Yaa is critical as the replacement of Hyp with 
its stereoisomer (4S)-hydroxy-L-proline (Hzp) results in a non-helical structure60. It was 
initially hypothesized that hydrogen bonding was responsible for the helical formation and 
stability of collagen61; however, studies involving replacement at Yaa with (4R)-fluoro-L-
proline (Fyp) proved that the preorganization of the triplet repeats was the more important 
factor62. 
Site-specific ncPro mutagenesis. There are several examples in the literature regarding the 
reliance of protein structure and function on a single proline residue. One of the first 
studies to use proline analogs as probes was done on a 5-hydroxytryptamine type 3 (5-HT3) 
receptor, containing a transmembrane region structurally and functionally homologous to 
the nicotinic acetylcholine receptor (nAChR) where a conserved proline (Pro8*) is located63.  
It was determined, through the use of several proline analogs, that the molecular 
mechanism for ion-gating relied on the cis-trans isomerization preferences of Pro8* and its 
functionality depended on the equilibrium between the cis and trans conformations of the 
proline peptide bond. The bulk of this thesis (Chapters 2-4) will describe an analogous 
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approach to understand the biophysics of the endocrine hormone (and important 
therapeutic) insulin and its implications for broadening the scope of protein engineering. 
Insulin. Blood glucose levels are tightly controlled in mammals through a sensitive 
regulatory system mediated by insulin, a 51-amino acid endocrine hormone composed of 
two disulfide-linked polypeptide chains (designated A and B). Upon binding to its receptor, 
insulin initiates a signaling cascade that accelerates glucose uptake and glycogen 
production. In diabetic patients, this system malfunctions, and glucose levels must be 
controlled through subcutaneous injections of insulin64. Diabetes is a chronic illness with 
two types: Type 1, where the patient’s β cells are destroyed due to autoimmunity and 
therefore, cannot produce insulin, and Type 2, where the patient becomes insulin-resistant. 
Currently, there are millions of people suffering from diabetes worldwide and this number 
has been projected to rise drastically in the next decade65—therefore, there exists a large 
unmet need that warrants the continued research and development of insulin therapy. This 
is because currently available prandial insulins are suboptimal in at least two respects. First, 
the onset of action after injection is delayed by slow dissociation of the insulin hexamer in 
the subcutaneous space, and second, insulin forms amyloid fibrils upon storage in 
solution64. Insulin can be stabilized with respect to fibrillation by addition of zinc and 
phenolic preservatives, which drive assembly of the R6 hexamer (Figure 1.1a)66-68.  Each 
subunit in the insulin hexamer adopts one of two conformational states (T or R), depending 
on the concentration of phenolic ligand69. Pharmaceutical formulations are prepared in the 
more stable R6 form, whereas the T-state is observed in the absence of phenolic ligands, 
most commonly in the form of T2-dimers70 (Figure 1.1a). 
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 Unfortunately, the R6 form of insulin is inactive and the lag time for dissociation 
delays the onset of action71. The C-terminus of the B-chain is important in mediating 
dimerization of insulin72,73, and the flexibility of the B-chain C-terminus is believed to 
contribute to aggregation through formation of amyloid fibrils74-76. 
Figure 1.1 | Oligomeric and in vivo behavior of insulin and therapeutic insulins. 
a, Schematic of hexamer disassembly (adapted from mechanism previously described67). Phenolic 
ligand (Ph), zinc ion (Zn2+), insulin monomer (triangle). Darker shading indicates the R-state of the 
hexamer. b, Structures of the B-chain C-termini of wild-type insulin (ProI, 1ZNJ) and RAI Aspart (AspI, 
1EV3). c, Relative insulin effects (curves not to scale) of different categories of therapeutic insulin 
(adapted from figure previously described66). 
 
Rapid-acting insulins (RAIs).  Mutation of ProB28 yields RAIs (i.e. RAI Aspart with AspB28, 
RAI Lispro with LysB28 and ProB29) by disrupting contacts that are critical for dimer 
formation67 and consequently leads to hexamer destabilization, which increases the rate of 
disassembly. Thus, the onset of action in diabetic patients for RAIs requires about half the 
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time required for regular (short-acting) insulins. There are drawbacks to current RAIs: 
replacement of Pro through conventional mutagenesis increases the flexibility and perturbs 
the trajectory of the protein backbone (Figure 1.1b). Proline’s dihedral angles are 
conformationally constrained due to its cyclic structure while all of the other 19 cAAs are 
acyclic, indicating that no cAA (other than proline) can accurately mimic the proline amide 
bond. We sought a means to disrupt the dimer interface without releasing the 
conformational constraints characteristic of proline by using ncAA mutagenesis52,69,77. 
Long-acting (basal) insulins. Normal functioning β cells are constantly secreting insulin at 
low levels78; to mimic this biological process, diabetics inject basal insulins once- or twice-a-
day in addition to either (or both) RAIs and regular insulins just prior to mealtime79. Basal 
insulins are made through either conjugation with fatty acids for binding to albumin or 
other serum proteins in the blood79, or formulated differently27 (e.g. insulin-protamine, 
NPH, is formulated with protamine to reduce solubility). Currently, the longest-acting basal 
insulin is insulin degludec (marketed as Tresiba), and depending on the patient it is injected 
either daily80 or thrice weekly81. 
Unmet needs and future outlooks. Even though insulin is one of the most studied and 
utilized proteins to date, there is room for improvements to be made. For example, an 
extremely undesirable side effect of insulin therapy is weight gain82 leading to interest in 
developing a ‘weight-neutral’ insulin therapy. An area of active interest comes from the 
observation that in non-diabetics, most of the insulin secreted is directed and cleared by the 
liver (where glycogenesis occurs)83. Current insulin therapies84 demonstrate a systemic 
uptake instead; the only preferentially hepato-specific insulin to date was PEGylated insulin 
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lispro85, made by Eli Lilly through conjugating a large polyethylene glycol (PEG) molecule at 
LysB29 through amine coupling. However, PEG-lispro was discontinued during Phase III 
clinical trials due to hepatic toxicity (presumably due to PEG accumulation86). Current 
insulin therapies also greatly rely on patient compliance (monitoring blood glucose levels 
and injecting insulin prior to meals) due to the lag time for onset of action, which has led to 
an unmet need for the development of glucose-responsive therapies. Current research for 
glucose-response therapies are focused on engineering novel insulin formulations to 
become activated in the presence of high blood glucose and withstand autonomous insulin 
pump use. Use of pumps with currently available insulins has been plagued by stability 
issues87,88; therefore, there is continued interest in further stabilizing insulins for long-term 
use in pumps89,90. The bulk of the work with glucose-responsive insulin formulations has 
focused on delivery vehicles91-93 that have not been validated clinically. 
Demonstrating how the therapeutic and physical properties of insulin can be modulated with 
ncAAs and expanding on methods to utilize ncAAs will give scientists another powerful new 
tool, one that fuses the concepts of medicinal chemistry and protein design, for the design of 
antibody-drug conjugates, bispecific antibodies, and other novel protein therapeutics. 
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Chapter 2 – Stereo-specific hydroxylation of 








Rapid-acting insulins (RAIs) have been produced by mutation of the proline residue at 
position 281,2 of the insulin B-chain (ProB28); mutation at this position disrupts the inter-
subunit interface in the hexamer and enhances the rate of disassembly, but it does not 
delay fibrillation. Here we show that replacement of ProB28 by (4S)-hydroxyproline (Hzp) 
yields an active form of insulin that dissociates more rapidly, and fibrillates more slowly, 
than the wild-type protein. In contrast to the behavior of known RAIs3, the rapid 
dissociation of Hzp-insulin (HzpI) is not accompanied by substantial destabilization of the 
insulin dimer; instead, a novel hydrogen bond interaction was found in the crystal structure 
of HzpI. The effects of hydroxylation are stereospecific; replacement of ProB28 by (4R)-
hydroxyproline (Hyp) causes little change in the rates of fibrillation and hexamer 




Insulin embodies a conundrum that often occurs with proteins: tradeoffs between 
stability and activity. Evolution has adapted proteins to behave a certain way to fulfill 
specific functions. For example, insulin is secreted when it is needed (to lower blood glucose 
levels) and is rapidly removed when it is not (when blood glucose reaches homeostasis)4. 
The insulin-producing and -secreting β cells in the islets of Langerhans, which are located in 
the pancreas, are able to lower high blood glucose concentrations to normal levels in a 
manner of minutes5,6. In order to elicit such a quick reaction, at any given time, hundreds of 
thousands of insulin molecules are stored in secretory granules5, but to avoid hypoglycemia, 
the unstable insulin monomer is also rapidly removed from circulation (by insulinase)7 once 
it is used. 
Figure 2.1 | Structure of dimeric insulin. 
Crystal structure of WT insulin (PDB: 3T2A) with residues involved in forming the dimer interface 
labelled. Lines represent hydrogen bonds (analyzed using UCSF Chimera software) between Residues 













The oligomeric behavior of insulin is due to the inter-subunit interactions8 (Figure 
2.1); for example, a micromolar solution of insulin, in the absence of any metal ions or 
phenolic ligands, is primarily dimeric9. However, at millimolar concentrations, insulin exists 
in mostly hexameric form10. Decades of insulin studies (i.e. mutagenesis at every residue) 
have determined that the oligomeric behavior of insulin is sensitive to perturbations at the 
C-terminus of the B chain (particularly residues B26-B30)2,11,12. 
Figure 2.2 | Proline analogs for study of hydroxylation 
Compound 1: L-proline (Pro); Compound 2: (2S,4S)-4-hydroxy-L-proline (Hzp); Compound 3: (2S,4R)-
4-hydroxy-L-proline (Hyp) 
 
Hydroxy-prolines. Previous work has shown that canonical mutations of ProB28 to acyclic, 
charged amino acids (i.e. aspartic acid, lysine) can modulate the dimerization of insulin1,13. 
However, acyclic amino acids can access more conformational space than proline14, which 
results in additional flexibility of the polypeptide backbone. Therefore, proline analogs (i.e. 
hydroxyprolines) were chosen to take advantage of a polar functional group with the added 
benefit of being able to  maintain proline backbone trajectory15 because of the restricted 
dihedral angles. In addition to their polarity and subsequent capacity for hydrogen-bonding, 
hydroxylation at the 4th position alters the endo/exo preference of the pyrrolidine ring and 
the cis/trans equilibrium of the amide backbone16-18. Calculations of cis/trans equilibrium 
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constants for Hzp and Hyp using model peptides show Hzp promotes a cis-amide, and Hyp, 
a trans-amide peptide bond19. 
Results and Discussion 
Recombinant expression of hydroxyinsulins. Non-diabetics produce insulin as a cleavage 
product from preproinsulin20 consisting of a signal peptide, followed by a B chain and A 
chain that are connected by a C-peptide.  This process has been adapted for the use of E. 
coli as an expression host starting with the expression of proinsulin (PI, preproinsulin 
without the signal peptide) followed by in vitro refolding and cleavage to mature insulin20,21. 
It has been previously reported22 that Hzp and Hyp can be incorporated into newly 
synthesized proteins in E. coli (Ec) with an overexpressed prolyl-tRNA synthetase (ProRS) 
under osmotic stress conditions. It is known that proline is an effective osmoprotectant  and 
proline transporters are upregulated in response to osmotic stress (i.e. NaCl at 
concentrations >300 mM)23. PI was placed under the inducible lac promoter on expression 
vector pQE80L with the gene encoding for Ec ProRS under its endogenous proS promoter 
located downstream between two transcriptional termination sites (pQE80PI-proS; Figure 
2.3a). Expression was done using proline-auxotrophic E. coli (strain CAG18515), and grown 
to mid-exponential phase before it was subjected to a medium shift to minimal medium 
with an extended depletion step to aid in the removal of intracellular proline and help 
enhance ncPro incorporation by selective pressure. After depletion, Hzp or Hyp, in the 
presence of 300 mM NaCl was added to allow for Hzp or Hyp uptake before cultures were 
induced with isopropyl-β-D-thiogalactopyranoside (IPTG) for 2 h. Expression of PI was 
confirmed via polyacrylamide gel electrophoresis (Figure 2.3bc). Incorporation levels were 
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assessed using matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS; 
Figure 2.3 d-f) and found to be approximately 90% by comparing areas of the peaks 
corresponding to the hydroxylated peptide at m/z = 1574 Da and the wild-type peptide at 
m/z = 1558 Da. 
Figure 2.3 | Insulin expression and incorporation of hydroxyprolines. 
a, Plasmid pQE80PI-proS containing gene construct proinsulin under inducible lac promoter and an 
overexpressed Ec ProRS for bacterial expression. b, c, SDS-PAGE of cell lysates with lanes labeled for 
pre-induction (PRE) and post-induction in minimal media supplemented with either nothing (19aa), 
Hzp (b) or Hyp (c), or Pro at 0.5 mM. c-e:  MALDI-MS traces of isolated proinsulin peptide fragment 
46RGFFYTPKTRRE57 obtained by gluC digestion. Peptide fragment masses corresponds to either wild 
type mass 1558 Da (d) or shifted mass 1574 Da if Hzp (e) or Hyp (f) is incorporated. Inset is whole 
protein MALDI-MS. Note the presence of desB30 insulin is <10%. All MALDI-MS spectra contain ion 
counts >103 
 
Refolding and insulin maturation. Inclusion bodies containing PI were extracted and 
resolubilized in denaturing buffer and purified using Ni-NTA affinity chromatography. 
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Elution fractions containing PI were combined, pH-adjusted, and subjected to oxidative 
sulfitolysis, and refolded. Typical soluble protein yields were ~30 mg/L for PI expressed in 
minimal media. The refolded protein was isolated by shifting to the solution to acidic 
conditions and then dialyzed, lyophilized and re-suspended in water for proteolytic cleavage 
(with trypsin and carboxypeptidase B) and liquid chromatography (HPLC) purification. Post-
HPLC fractions containing mature insulin were lyophilized, re-suspended in phosphate 
buffer prior to verification by whole protein MALDI-MS (Figure 2.3c-e, inset). Recovery of 
insulin from soluble PI was estimated to be 25-50%. Insulin fractions were stored at -80°C 
and thawed on ice prior to use.  
Figure 2.4 | Hydroxyinsulins retain biological activity. 
a, Immunoblot of phosphorylated insulin receptor using HEK293 cells treated with insulin (200 nM in 
PBS, pH 7.4) or vehicle. Whole cell lysates were then run on an SDS-PAGE gel and transferred to 
nitrocellulose membrane to detect insulin receptor (IR) and IR phosphorylation. β-actin immunoblot 
shown as loading control.  Lane 1: Vehicle (PBS); Lane 2: 10% ProI serving as a second negative 
control due to presence of 10% wt in HzpI and HypI preparations; Lane 3: HzpI; Lane 4: HypI; Lane 5: 
ProI. b, Reduction of blood glucose following subcutaneous injection of 35 μg/kg insulins into 
streptozocin-induced diabetic mice. Glucose levels were measured post-injection via tail vein 
sampling. ProI, AspI, HzpI, HypI or vector were formulated as described24. Error bars denote one 
standard deviation (n = 3). 
 
Recombinant HzpI and HypI are biologically active. We verified that recombinant insulins 
can bind to the insulin receptor (IR) and initiate its signaling cascade (via phosphorylated IR) 
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in an in vitro cell culture assay25 (Figure 2.4a). Recombinant insulins were also able to lower 
blood glucose levels in streptozotocin (STZ)-induced diabetic mice (Figure 2.4b) in vivo; the 
presence of 10% ProI in HypI and HzpI preparations (Figure 2.3de, Table 2.1) is not enough 
to initiate blood glucose lowering action (data shown in Chapter 3, Figure 3.4a).  This was 
expected per literature as residues B26-30 are not involved in IR binding26. Recombinant 
insulin preparations for in vivo injections were verified to be endotoxin-free and devoid of 
common microorganisms (E. coli and yeast) by sterility tests. 
Table 2.1 | Biophysical characteristics of hydroxyinsulin. 
Errors are given as one standard deviation (n ≥ 4). *Quantified by MALDI-MS on proinsulin peptide 










Lag Time (h) 
KD dimer 
(µM) 
L-Proline -- ProI 90.4 ± 4.2 5.1 ± 1.5 9 μM27 
Hzp 91.3 ± 1.8 HzpI** 53.6 ± 3.7 19.6 ± 2.6 ~25 μM  
Hyp 88.2 ± 1.2 HypI** 87.0 ± 10 5.5 ± 1.2 >200 μM 
L-Aspartic acid -- AspI 42.7 ± 4.3 5.3 ± 1.0 >500 μM13 
Incorporation of hydroxyprolines alters insulin dimerization. In the absence of Zn2+ and 
phenolic preservatives, insulins dimerize with a dissociation constant (KD) of approximately 
10 µM.  In contrast, KD for RAIs is typically >500 µM, and it is believed that destabilization of 
the dimer interface causes the accelerated onset of insulin action after subcutaneous 
injection13,27,28. Monomeric forms of insulin give rise to characteristic circular dichroism (CD) 
spectra with distinct minima at 208 and 222 nm (e.g., AspI; Figure 2.5a). Dimerization 
causes a loss of negative ellipticity at 208 nm (e.g., ProI; Figure 2.5a). At 60 µM, HypI 
appears to be monomeric (with a CD spectrum nearly identical to that of AspI; Figure 2.5a) 
while the spectrum of HzpI suggests a dimeric insulin (Figure 2.5a). Sedimentation velocity 
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(SV) and sedimentation equilibrium (SE) experiments were consistent with the results of the 
CD analysis (data not shown). SE data were fitted to a model of monomer-dimer-hexamer 
self-association (SEDPHAT)29,30, and yielded monomer-dimer dissociation constants (KD) 
of >200 µM and 25 µM for HypI and HzpI, respectively. 
Figure 2.5 | Hydroxylation at ProB28 modulates insulin dimerization, dissociation kinetics, 
and stability. 
a, Far UV CD spectra collected on 60 μM insulins in 10 mM phosphate buffer, pH 8.0 at 25°C. b, Insulin 
hexamer dissociation following sequestration of Zn2+ by terpyridine.  Zn2+-(terpy) signal was 
monitored at 334 nm and fitted to a mono-exponential decay. HzpI and HypI contain 10% ProI. The 
curves for HypI and ProI are indistinguishable in this plot. c, Representative fibrillation curves for 60 
µM insulins (37°C, 960 RPM; n=4). Insulin fibrils were detected by the rise in Thioflavin T (ThT) 
fluorescence that occurs upon binding to fibrillar aggregates. 
 
Hydroxylated insulins behave differently from wild-type insulin. Previous studies of RAIs 
have shown that destabilization of the dimer interface correlates with accelerated 
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dissociation of the hexamer and rapid onset of insulin action31,32.  Triggered dissociation of 
Zn2+-hexamers by addition of the chelating agent terpyridine33 revealed nearly identical 
rates of dissociation for HypI and ProI, (𝜏1/2 = 87.0 ± 10 s and 90.4 ± 4.2 s, respectively; 
Figure 2.5b) while HzpI exhibited kinetics similar to those of AspI (𝜏1/2 = 53.6 ± 3.7 s and 42.7 
± 4.3 s, respectively; Figure 2.5b).  Replacement by Hyp destabilizes the dimer but has 
essentially no effect on hexamer dissociation, while introduction of Hzp does not affect 
dimer stability but enhances rate of hexamer disassembly. Our results indicate that 
dimerization of the insulin monomer and dissociation kinetics of the insulin hexamer can be 
decoupled, and thus we speculate that there are other factors, besides destabilization of 
the dimer, that govern 𝜏1/2. 
Figure 2.6 | Micrographs of insulin fibrils. 
Transmission electron micrographs of (a) ProI (b) HzpI, and (c) HypI fibrils. Scale bar 100 nm.  
 
Insulin therapy is associated with amyloidogenesis34. While there is a lot known 
about insulin fibrillation11,35-46, and some studies have used ncAAs24,31,47, we cannot predict 
what effects hydroxylation at position B28 will have—thus, each of the insulin variants was 
subjected to fibrillation lag time analysis (Figure 2.5c)48. We found similar times to onset of 
fibrillation for HypI, ProI, and AspI; in contrast, HzpI is markedly more resistant to 
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aggregation. Transmission electron microscopy (TEM) imaging of insulin fibrils found similar 
structural features (Figure 2.6) between ProI, HzpI, and HypI, indicating that hydroxylation 
at B28 does not influence the final aggregation state. 
Figure 2.7 | Alignment at position B28. 
a, d, Alignment of T2 ProI (tan, PDB:3T2A), and T2-HzpI (grey) or T2-HypI (blue) centered on position 
B28. b, e, Alignment of R6-ProI (tan) and R6-HzpI (grey) or R6-HypI (blue) highlighting the overlap of 
the backbone at the C-terminus. c, f, Alignment of R6 insulins (ProI, and HzpI or HypI), and AspI 
(orange, PDB: 1ZEG) centered on position B28 highlighting the similarity of the polypeptide backbone 
for HzpI and HypI, as opposed to AspI, compared to ProI.  
 
Crystal structure of HzpI reveals a novel hydrogen bond in the dimer interface. To elucidate 
the molecular origins of the dissociation and fibrillation behavior of HypI and HzpI, we 
examined crystal structures of both T- and R-states. Hydroxylation at ProB28 does not cause 
substantial perturbation of the backbone chain trajectory at the C-terminus (Figure 2.7) or 
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the overall insulin structure.  In comparison with ProI, the backbone root-mean-square-
deviation (RMSD) values of HypI and HzpI are 0.31 Å (T2- HypI), 0.44 Å (T2- HypI), 0.38 Å (R6- 
HypI), and 0.69 Å (R6- HypI)49. The most notable feature of the HzpI structures is the 
proximity of the hydroxyl group of Hzp to the backbone carbonyl oxygen atom of GluB21′, 
which lies across the dimer interface (denoted by prime; Figure 2.8b,e). The inter-oxygen 
distances (2.8 Å in the T2 structure, 2.7 Å in R6), are consistent with the formation of strong 
hydrogen bonds between the hydroxyl group of HzpB28 and the backbone carbonyl of 
GluB21′ in both T2-HzpI and R6-HzpI structures. An analogous hydrogen bond has been 
observed in a structure (PDB ID: 1ZEH) of R6-AspI co-crystallized with m-cresol50; here, the 
phenolic ligand serves as the hydrogen-bond donor. Although the significance of this 
hydrogen bond has not been discussed in the literature, we suggest that it may play an 
important role in determining the relative stabilities of the insulin species involved in 
dissociation and fibrillation. In contrast to the (4S)-hydroxyl group of Hzp, the (4R)-hydroxyl 
of HypB28 does not contact any crystallographically resolved hydrogen bond acceptor in the 
T2-structure (Figure 2.8c), and appears to bond to an ordered water molecule in the R6-
hexamer (Figure 2.8f). The absence of new hydrogen-bonding interactions is consistent with 
the unaltered dissociation and fibrillation kinetics of HypI. 
We suggest that the hydrogen bond between Hzp and GluB21′ may stabilize the 
dimer relative to the hexamer, or perhaps reduce the energy of the transition state for the 
conformational change from the R-state to T-state, and thereby increase the rate of 
disassembly. In addition, we propose that this hydrogen bond may prevent the C-terminus 
of the B chain from fraying and initiating fibril formation. Regardless of the mechanism, 
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these results demonstrate the usefulness of ncAA mutagenesis, an approach that fuses the 
concepts of medicinal chemistry and protein design, and paves the way to further engineer 
insulin (discussed further in Chapters 3-4) and other therapeutic proteins. 
Figure 2.8 | Crystal structures of HzpI and HypI. 
In tan (left), wt insulins from PDB (3T2A, 1ZNJ) highlighting the distance between the γ-carbon of 
ProB28 and its closest neighbors, backbone carbonyl oxygen atoms of GlyB20’ and GluB21 in the T2 
dimer (a) and R6 hexamer (d) forms.  In grey (middle), HzpI in the T2 dimer (b) and R6 hexamer (e) 
forms. In blue (right), HypI in the T2 dimer (d) and R6 hexamer (g) forms. 
 
Materials and Methods 
Materials.  All canonical amino acids and (4R)-hydroxy-L-proline (Hyp) were purchased from 
Sigma.  (4S)-hydroxy-L-proline (Hzp) was purchased from Bachem Americas.  All solutions 
and buffers were made using double-distilled water (ddH2O). 
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Strains and plasmids.  The proinsulin (PI) gene with an N-terminal hexa-histidine tag (6xHIS), 
and flanked by EcoR1 and BamH1 cut sites was ordered as a gBlock (Integrated DNA 
Technologies).  Both the gBlock and vector pQE80L for IPTG-inducible expression were 
digested with EcoRI and BamHI.  Linearized vector pQE80L was dephosphorylated by 
alkaline phosphatase (NEB).  Ligation of the digested PI gene and linearized vector yielded 
plasmid pQE80PI (to produce ProI). To make plasmid pQE80PI-proS (to produce HzpI and 
HypI): Genomic DNA was extracted from E. coli strain DH10β using DNeasy Blood and Tissue 
Kit (Qiagen).  Primers (Integrated DNA Technologies) were designed to amplify the E. coli 
proS gene, encoding prolyl-tRNA synthetase, under constitutive control of its endogenous 
promoter, from purified genomic DNA, and to append NheI and NcoI sites.  The digested 
proS gene was then inserted into pQE80PI between transcription termination sites by 
ligation at NheI and NcoI restriction sites. Proline-auxotrophic E. coli strain CAG18515 was 
obtained from the Coli Genetic Stock Center at Yale University.  Prototrophic E. coli strain 
BL-21 was used for rich media expression of canonical insulins (ProI, AspI). Site-directed 
mutagenesis of pQE80PI at B28 was performed to make plasmid pQE80PI-asp, which differs 
from pQE80PI by three nucleotides that specify a single amino acid mutation to aspartic 
acid. All genes and plasmids were confirmed by DNA sequencing.   
Protein expression. Plasmids pQE80PI and pQE80PI-asp were transformed into BL21 cells 
and grown on ampicillin-selective agar plates.  A single colony was used to inoculate 5 mL of 
Luria-Bertani (LB) medium and grown overnight; the resulting saturated culture was used to 
inoculate another 1 L of LB medium.  All expression experiments were conducted at 37°C, 
200 RPM in shake flasks (Fernbach 2.8 L flasks, Pyrex®). Each culture was induced with 1 
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mM IPTG at mid-exponential phase (OD600 ~0.8).  For incorporation of Hyp and Hzp, 
pQE80PI-proS was transformed into CAG18515 cells, which were grown on ampicillin-
selective agar plates. To facilitate growth, a single colony was used to inoculate 25 mL of LB 
medium and the culture was grown overnight prior to dilution into 1 L of 1X M9, 20 aa 
medium (8.5 mM NaCl, 18.7 mM NH4Cl, 22 mM KH2PO4, 47.8 mM Na2HPO4, 0.1 mM CaCl2, 1 
mM MgSO4, 3 mg/L FeSO4, 1 μg/L of trace metals (Cu2+, Mn2+, Zn2+, MoO42-), 35 mg/L 
thiamine hydrochloride, 10 mg/L biotin, 20 mM D-glucose, 200 mg/L ampicillin with 50 mg/L 
of L-amino acids, each).  At an appropriate cell density (OD600 ~0.8), the culture was 
subjected to a medium shift; briefly, cells were centrifuged and washed with saline prior to 
resuspension into 0.8 L of 1.25X M9, 19 aa (1X M9, 20 aa medium without L-proline).  After 
cells were further incubated for 30 min to deplete intracellular L-proline, 200 mL of 5X 
additives (1.5 M NaCl, 2.5 mM Hyp or Hzp) was added to the culture.  After another 15 min 
of incubation at 37°C to allow amino acid uptake prior to induction, IPTG was added to a 
final concentration of 1 mM.  At the end of 2 h, cells were harvested by centrifugation and 
stored at -80°C until further use.  
Cell lysis and refolding from inclusion bodies. Cells were thawed on the benchtop for 15 min 
prior to resuspension in lysis buffer (B-PER®, 0.5 mg/mL lysozyme, 50 U/mL benzonase 
nuclease). Cells were gently agitated at RT for 1 h prior to centrifugation (10 000 g, 10 min, 
RT); supernatant was discarded and the pellet was washed thrice: once with wash buffer (2 
M urea, 20 mM Tris, 1% Triton X-100, pH 8.0) and twice with sterile ddH2O; centrifugation 
followed each wash and the supernatant was discarded. The final washed pellet containing 
inclusion bodies (IBs, ~50% PI) was re-suspended in Ni-NTA binding buffer (8 M urea, 300 
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mM NaCl, 50 mM NaH2PO4, pH 8.0) overnight at 4°C or at RT for 2 h, both with gentle 
agitation.  The suspension was centrifuged to remove insoluble debris; the remaining pellet 
was discarded and the supernatant was mixed with pre-equilibrated Ni-NTA resin (Qiagen) 
at RT for 1 h in order to purify PI from the IB fraction. Unbound proteins in the IB fraction 
were collected in the flow-through (FT), and the resin was washed with Ni-NTA wash buffer 
(8 M urea, 20 mM Tris base, 5 mM imidazole, pH 8.0) and Ni-NTA rinse buffer (8 M urea, 20 
mM Tris base, pH 8.0) prior to stripping PI from the resin with Ni-NTA elution buffer (8 M 
urea, 20 mM Tris base, pH 3.0). Fractions (IBs, FT, W, elution) were collected and run under 
reducing conditions on SDS-PAGE (Bis/Tris gels, Novex®); elution fractions containing PI 
were pooled and solution pH was adjusted to 9.6 with 6 N NaOH in preparation for 
oxidative sulfitolysis. Oxidative sulfitolysis was performed at RT for 4 h, with the addition of 
sodium sulfite and sodium tetrathionate (0.2 M Na2SO3, 0.02 M Na2S4O6); the reaction was 
quenched by 10-fold dilution with ddH2O. To isolate PI from the quenched solution, the pH 
was adjusted to between 3.5 and 4.5 by adding 6 N HCl dropwise; the solution became 
cloudy. The solution was centrifuged (10 000 g, 10 min, RT) and supernatant discarded. The 
PI pellet was then re-suspended in refolding buffer (0.3 M urea, 50 mM glycine, pH 10.6) 
and protein concentration was estimated by the bicinchoninic acid assay (BCA assay, 
Pierce®). The concentration of PI was adjusted to 0.5 mg/mL. Refolding was initiated by 
addition of β-mercaptoethanol to a final concentration of 0.5 mM and allowed to proceed 
at 12°C overnight with gentle agitation (New Brunswick® shaker, 100 RPM). Post-refolding, 
soluble PI was harvested by adjusting the pH of the solution to 4-5 by dropwise addition of 6 
N HCl and by high speed centrifugation to remove insoluble proteins. The supernatant was 
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adjusted to pH 8-8.5 by dropwise addition of 6 N NaOH and dialyzed against fresh PI dialysis 
buffer (7.5 mM sodium phosphate buffer, pH 8.0) at 4°C with five buffer changes to remove 
urea. The retentate (PI in dialysis buffer) was then lyophilized and subsequently stored at -
80°C until further processing. Typical yields were 25-50 mg PI per L of culture (25-30 mg/L 
for non-canonical PI, 40-50 mg/L for canonical PI expression in rich media) 
Proteolysis and chromatographic (HPLC) purification. The dry PI powder was re-dissolved in 
water to a final concentration of 5 mg/mL PI (final concentration of sodium phosphate 
buffer is 100 mM, pH 8.0). Trypsin (Sigma-Aldrich) and carboxypeptidase-B (Worthington 
Biochemical) were added to final concentrations of 20 U/mL and 10 U/mL, respectively to 
initiate proteolytic cleavage. The PI/protease solution was incubated at 37°C for 2.5 h; 
proteolysis was quenched by addition of 0.1% trifluoroacetic acid (TFA) and dilute HCl to 
adjust the pH to 4. Matured insulin was purified by reversed phase high-performance liquid 
chromatography (HPLC) on a C18 column using a gradient mobile phase of 0.1% TFA in water 
(solvent, A) and 0.1% TFA in acetonitrile (ACN; solvent, B). Elution was carried from 0% B to 
39% B with a gradient of 0.25% B per minute during peak elution. Fractions were collected 
and lyophilized, and the dry powder was re-suspended into 10 mM sodium phosphate, pH 
8.0. Insulin-containing fractions were verified by matrix-assisted laser 
desorption/ionization-mass spectrometry (MALDI-MS; Voyager MALDI-TOF, Applied 
Biosystems) and SDS-PAGE to ensure identify and purity. Typical yields were 5-10 mg insulin 




Verification of Hyp and Hzp incorporation levels and maturation.  A 30 μL aliquot of PI 
solution (8 M urea, 20 mM Tris, pH 8) was subjected to cysteine reduction and alkylation (5 
mM DTT, 55°C, 20 min; 15 mM iodoacetamide, RT, 15 min, dark) prior to 10-fold dilution 
into 100 mM NH4HCO3, pH 8.0 (100 μL final volume). Peptide digestion was initiated with 
0.6 μL of gluC stock solution (reconstituted at 0.5 μg/μL with ddH2O, Promega) at 37°C for 
2.5 h. The reaction was quenched by adding 10 μL of 5% TFA and immediately subjected to 
C18 ZipTip (Millipore) peptide purification and desalting according to the manufacturer’s 
protocol.  Peptides were eluted in 50% ACN, 0.1% TFA; the eluent was then diluted three-
fold into matrix solution (saturated α-cyanohydroxycinnamic acid in 50% ACN, 0.1% TFA) 
and analyzed by mass spectrometry (Voyager MALDI-TOF, Applied Biosystems).  Hyp and 
Hzp incorporation levels were analyzed prior to and after refolding; incorporation 
percentage was calculated by comparing total AUC (area under the curve, arbitrary units) of 
the non-canonical peak (1573 Da for the proinsulin peptide containing B28Hzp or B28Hyp, 
approximately 5824 Da for intact HzpI and HypI) with total AUC of its wild-type counterpart 
(1557 Da and 5808 Da, respectively). Maturation of HypI and HzpI was analyzed after HPLC 
purification. TFA (1.6 μL, 5%) was added to 15 μL mature insulin solution (10 mM phosphate 
buffer pH 8.0) and subjected to C18 ZipTip (Millipore) peptide purification and desalting per 
the manufacturer’s protocol. MALDI-MS conditions described above were used to confirm 
insulin maturation.   
Insulin receptor (IR) phosphorylation immunoblot. In vitro analysis of insulin receptor (IR) 
phosphorylation was performed using HEK293 cells according to a previous report25.  
Briefly, HEK293 cells were maintained in a 37°C, 5% CO2 humidified incubator chamber 
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using Dulbecco’s modified Eagle’s medium with 4.5 g/L glucose, 2 mM L-glutamine and 
phenol red (DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life 
Technologies), 5% penicillin/streptomycin (P/S, Life Technologies). Every 3 days, at 
approximately 80% confluency, cells were subcultured and seeded in a 6-well plate at a cell 
density of 8x103 cells / cm2 (or 8x104 cells per well) for 24 h prior to insulin addition. Insulins 
or vehicle were added directly to the medium at 200 nM (10 μL of a 50 μM solution in 
vehicle PBS) and incubated for 10 min prior to PBS washes to remove excess medium. 
HEK293 cells were lysed on-plate using IP Lysis Buffer (ThermoFisher, Pierce) with 50 U/mL 
benzonase nuclease (Sigma-Aldrich) for 20 min at 4°C; lysates were precipitated using ice 
cold acetone and re-suspended in 8 M urea, 20 mM Tris, pH 10.0. The protein concentration 
in the lysate was quantified by the BCA assay (ThermoFisher, Pierce) according to the 
manufacturer’s protocol and normalized for even protein loading across lanes. Lysates were 
separated by SDS-PAGE (4-12% Novex Bis/Tris SDS-PAGE gels, Life Technologies) in 
duplicate and transferred to a nitrocellulose membrane (Hybond ECL, GE Healthcare) using 
a wet transfer system. The membrane was blocked at RT in 5% nonfat milk in Tris-buffer 
saline with 0.1% Tween 20 (TBS/Tween) and washed with TBS/Tween prior to blotting with 
antibodies. Primary antibodies for insulin receptor, phosphorylated insulin receptor (from 
Cell Signaling Technologies) and β-actin (as loading control, from Invitrogen) were added at 
1:1000 dilution in TBS/Tween with gentle agitation either at RT for 4 h or overnight at 4°C. 
Blots were washed and secondary antibodies (Invitrogen) were added at 1:2000 dilution in 




Reduction of blood glucose in diabetic animals. NODscid (NOD.CB17-Prkdcscid/J) mice were 
obtained from Jax Mice (Bar Harbor, Maine). Mice were maintained under specific 
pathogen-free conditions, and experiments were conducted according to procedures 
approved by the Institutional Animal Care and Use Committee at the City of Hope. Adult (8- 
to 12-week-old) male NODscid mice were injected intraperitoneally (50 mg/kg/day for 3 
consecutive days) with freshly prepared streptozotocin (STZ) in 0.05 M citrate buffer, pH 4.5 
to induce diabetes. Diabetes was confirmed 3 weeks after the last dose of STZ by detection 
of high glucose levels (defined as >200 mg/dL), measured by using a glucomonitor 
(FreeStyle; Abbott Diabetes Care, Alameda, CA) in blood (10 μL) sampled from the lateral 
tail vein. Insulin analogs concentrations were determined from A280 measurements using a 
molar extinction coefficient of 6080 M-1 cm-1 and diluted to 100 µg/mL into a formulation 
buffer according to a previous report47. Insulin analogs in solution were injected 
subcutaneously at the scruff and blood glucose was measured at the indicated time points. 
Circular Dichroism. Spectra were collected in a 1 cm quartz cuvette at an insulin 
concentration of 60 μM in 50 mM sodium phosphate buffer pH 8.0. Data were collected 
from 185 nm to 250 nm, with step size of 0.25 nm and averaging time of 1 s on a Model 410 
Aviv Circular Dichroism Spectrophotometer; spectra were averaged over 3 repeat scans. A 
reference buffer spectrum was subtracted from the sample spectra for conversion to mean 
residue ellipticity.  
Analytical Ultracentrifugation. Sedimentation velocity (SV) and sedimentation equilibrium 
(SE) experiments were carried out on an XL-1 AUC (BeckmanCoulter). SV experiments were 
conducted with insulin samples dialyzed against 50 mM Tris, 0.1 mM EDTA, pH 8.0, which 
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also served as the reference buffer. Two sector cells with sapphire windows were filled with 
sample and reference buffer. These cells were centrifuged at 50,000 RPM with absorbance 
data collected at 280 nm, or for concentrations above 1 mg/mL, 281 nm or 287 nm. SV data 
were analyzed in SEDFIT with the c(s) algorithm for a continuous distribution51. Buffer 
density and viscosity were calculated from SEDNTERP; the partial specific insulin volume 
used was 0.73552. SE experiments were conducted with insulin samples dialyzed against 50 
mM Tris, 0.1 mM EDTA, pH 8.0, which also served as the reference buffer. Two sector cells 
with sapphire windows were filled with sample and reference buffer and centrifuged at 
15,000, 24,000, 36,000, and 50,000 RPM with absorbance data collected at 280 nm. 
Equilibrium was ascertained by analysis in SEDFIT and non-equilibrated scan speeds were 
excluded from data analysis. SE and SV data from multiple concentrations were fitted to a 
monomer-dimer-hexamer reversible self-association model in SEDPHAT with best model 
chosen by inspection of residuals as well as critical  value deviation53. Radial dependent 
baselines were computationally determined using TI noise. Figures were generated using 
GUSSI54. 
Hexamer Dissociation Assay. Insulins were quantified by both UV absorbance (NanoDrop 
Lite, ThermoFisher) and BCA assay, and normalized to 125 μM insulin prior to dialysis 
against 50 mM Tris/perchlorate, 25 μM zinc sulfate, pH 8.0 overnight at 4°C using a D-tube 
dialyzer (Millipore Corp.) with MWCO of 3.5 kDa.  Aliquots of dialyzed insulin solution were 
mixed with phenol to yield samples of the following composition: 100 μM insulin, 20 μM 
zinc sulfate, 100 mM phenol. Dissociation was initiated by addition of terpyridine (Sigma-
Aldrich) to a final concentration of 0.3 mM from a 0.75 mM stock solution. A Varioskan 
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multimode plate reader (Thermo Scientific) was used to monitor absorbance at 334 nm. 
Kinetic runs were done at least in triplicate, and the data were fit to a mono-exponential 
function using Origin software.  Post assay insulin samples were pooled and sample quality 
was determined by SDS-PAGE. 
Fibrillation Assay.  Insulin samples (60 μM in 10 mM phosphate, pH 8.0) were centrifuged at 
22 000 g for 1 h immediately after addition of thioflavin T (ThT) (EMD Millipore) to a final 
concentration of 1 μM. Samples were continuously shaken at 960 RPM on a Varioskan 
multimode plate reader at 37°C, and fluorescence readings were recorded every 15 min for 
48 h (excitation 444 nm, emission 485 nm).  Assays were run in quadruplicate, in volumes of 
200 μL in sealed (Perkin-Elmer), black, clear-bottom 96 well plates (Grenier BioOne). 
Transmission electron microscopy. Insulin samples (60 μM in 10 mM phosphate, pH 8.0) 
were continuously agitated in microfuge tubes at 42°C, 960 RPM for 48 h in a ThermoMixer 
to obtain fibrils. Samples were stained onto 200 mesh copper grids (formar/carbon coated, 
plasma cleaned) with 1% uranyl acetate.  Imaging was done by Alasdair McDowell at the 
Beckman Institute’s Center for Transmission Electron Microscopy on a Tecnai T12 LaB6 120 
eV Transmission Electron Microscope. 
Crystallographic Studies. Insulin crystals were obtained from sitting drop trays set using a 
Mosquito robot (TTP Labtech). Drops were set by mixing 0.4 μL insulin solution with 0.4 μL 
well solution. Well solution conditions were as follows: 462.5 mM sodium citrate, 100 mM 
HEPES, pH 8.25 for 5HQI; 300 mM Tris, 0.5 mM zinc acetate, 8.5% acetone, 0.5 M sodium 
citrate pH 8.0 for 5HPR; 300 mM Tris, 17 mM zinc acetate, 1% phenol, 7.5% acetone, 2.675 
M sodium citrate pH 8.0 for 5HRQ; 300 mM Tris, 17 mM zinc acetate, 1% phenol, 7.5% 
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acetone, 1.95 M sodium citrate pH 8.0 for 5HPU. Cells were cryoprotected in a mother 
liquor containing 30% glycerol prior to looping and flash freezing in liquid nitrogen. Data 
were collected at SSRL beamline BL12-2 using a DECTRIS PILATUS 6M pixel detector. Initial 
indexing and scaling was performed with XDS; for some structures, data were re-scaled in 
alternative space groups using Aimless55. Initial phases were generated by molecular 
replacement in PHASER with 3T2A (5HQI and 5HPR) or 1EV3 (5HRQ and 5HPU)56. Structure 
refinement was carried out in Coot and Refmac557,58. Data were deposited in the PDB with 
the following codes: 5HQI (T2-HzpI), 5HPR (T2-HypI), 5HRQ (R6-HzpI), 5HPU (R6-HypI). All 
distances and contacts were computed using crystallography software (UCSF Chimera). 
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Chapter 3 – Understanding the effects of 




Mutating the proline residue at position 28 (ProB28) of the insulin B-chain disrupts the 
inter-subunit interface in the hexamer, enhances the rate of disassembly, and has served as 
the basis for producing rapid-acting insulins (RAIs); however, previous mutations here have 
not been shown to delay the onset of fibrillation1,2. The fluoroprolines, (2S,4S)-4-fluoro-L-
proline (Fzp), (2S,4R)-4-fluoro-L-proline (Fyp), and (4,4)-difluoro-L-proline (dFp), when 
incorporated at proline positions in several proteins, have resulted in stabilizing effects3-7. 
Here we show that replacement of ProB28 by fluoroprolines yields forms of insulin with 
unique properties. Fzp-insulin (FzpI) has a similar hexamer dissociation rate and a marginally 
delayed lag time to fibril formation compared to the wild-type protein (ProI), while Fyp-
insulin (FypI) dissociates like known RAIs, but forms fibrils more readily than ProI. dFpI-
insulin (dFpI) has intermediate dissociation rate (between ProI and RAIs) but is, surprisingly, 
also the most stable fluoroinsulin. Our results demonstrate that the biophysical behavior of 
insulin is sensitive to fluorination at ProB28, and crystal structures suggest that CH/π 
interactions between ProB28 and TyrB26 may play a larger role in insulin biophysics than 




Fluorine and Fluorinated Proteins. Fluorine has a long and storied use in medicinal 
chemistry8 because of its small size (minimal structural perturbations) and hydrophobicity. 
Fluorine is highly electronegative, rendering the carbon-fluorine (C-F) bond extremely 
strong and polarized9, which can influence lipophilicity (to cross cell membranes), tune pKa, 
and solubility10.  In addition, the fluorination of small molecules has generally led to 
increased potency (e.g., Fludrocortisone is more potent than the parent compound 
Hydrocortisone)8. Fluorine does not appear11 in natural proteins, although there are known 
organofluoro molecules that have been found in a handful of species12. Protein engineers 
have taken advantage of fluorine’s expanded hydrophobic surface area and electronegative 
effects8,9,13-15 through replacement of interacting residues in leucine zipper (Figure 3.1) and 
collagen helices with fluorinated non-canonical amino acids (ncAAs). 
Figure 3.1 | Leucine zipper used in fluorination studies. 
a, Consensus motif for coiled coils in helical wheel representation. b, Parallel coiled-coil structure of 
leucine zipper GCN4 (PDB: 1GD2) with leucines colored (coral) and side chain represented by ball-and-
stick. Van der Waals (vdW) contacts between leucines at the core of the helices are depicted with the 




Fluorination of leucines. Interactions between leucine residues drive the self-association16 of 
coiled coils. Leucines at the d positions (Figure 3.1a) are critical to dimerization17 because 
they form hydrophobic van der Waals (vdW) contacts with one another (Figure 3.1b). 
Several studies11,18 on leucine zippers have detailed the stabilizing effects of fluorinated 
surfaces. It has been theorized that fluorination largely retains the canonical hydrophobic 
character, while allowing the slightly larger and more hydrophobic fluorinated groups to 
pack densely, which effectively stabilizes the helical structure of coiled coils19. 
Fluoroproline. Several studies have investigated the effects of fluoroprolines in 
proteins5,6,20. The natural helical structure of collagen relies on both hydrogen bonding 
interactions and inductive effects from the hydroxyl group of (2S,4R)-4-hydroxy-L-proline 
(Hyp)21. Substitution of Hyp with (2S,4R)-4-fluoro-L-proline (Fyp) in collagen results in a 
hyper-thermostable protein3 even though Fyp is unable to form hydrogen bonding 
interactions; however, the fluorine of Fyp is more electronegative than the oxygen from the 
hydroxyl group of Hyp. Therefore, from these experimental results, it was concluded that 
collagen stability is more reliant on inductive effects than hydrogen bonding 
interactions22,23. However, the information obtained from a simple structure, such as 
collagen, is not readily applicable to globular proteins, which typically contain higher order 
structures with complex interactions between residues.  
Folding studies on fluorinated globular proteins. Cis-trans isomerization of the peptide bond 
between any residue X and Pro (X-Pro) is known to govern rates of protein folding24. This 
rate-determining folding step has been experimentally determined for bovine pancreatic 
ribonuclease A25, ubiquitin5 and E. coli thioredoxin6,26; all three of these proteins require at 
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least one cis X-Pro to proceed to its correctly folded form. Fluoroprolines (Figure 3.2) have 
different cis-trans equilibrium constants; in model peptide studies, (2S,4S)-4-fluoro-L-
proline (Fzp) prefers the cis conformation approximately 3 times more than Pro13. For 
example, replacement of the cis-Pro in thioredoxin by Fzp leads to an 8-fold increase in the 
protein folding rate26. 
Stability studies on fluorinated β2-microglobulin. The cis-trans isomerization of the proline 
peptide bond (Figure 3.2b) in proteins is dynamic and has consequences in vivo. Studies on 
a neurotransmitter channel (5-hydroxytrptamine type 3 receptor) found that its gatekeeper 
residue (for ion transport) was a critical proline, which when replaced with proline analogs 
of differing cis-trans isomerization preferences can be fine-tuned for electrophysiology27. It 
has also been shown in several proteins that protein aggregation rates are also directly 
correlated with cis-trans isomerism at critical proline residues28-31. For example, human β2-
microglobulin (β2m), a component of the class I major histocompatibility complex (MHC I)32, 
is stable under physiological conditions, but readily aggregates in patients with kidney 
disease who are undergoing long-term hemodialysis33. Due to its role in the immune 
system, β2m has been studied extensively34-36 and NMR spectroscopy of both fibrillar and 
crystalline β2m states identified proline at position 32 (Pro32)37 as the “switch” for amyloid 
formation. In soluble or crystalline form, β2m contains a cis-Pro32, while the aggregated 
state contains Pro32 in primarily trans peptide form. Fluoroprolines, with varying cis-trans 
isomerization equilibrium constants (Ktrans/cis ranges from 2.5 to 6.7, compared to Ktrans/cis of 
4.7 for Pro)12,38,  were site-specifically incorporated into β2m at Pro32 through semi-
synthesis. Unsurprisingly, Fzp, which of the fluoroprolines has the greatest preference for 
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the cis-amide bond (Ktrans/cis of 2.5), when incorporated into β2m showed the greatest 
propensity to deter aggregation39. Notably, the effects of cis-trans isomerization and 
stability by fluorination were not decoupled in these or follow-up studies40. 
Figure 3.2 | Proline analogs for fluorination study. 
a, Chemical structures for compound 1: L-proline; Compound 2: (2S,4S)-4-fluoro-L-proline (Fzp); 
Compound 3: (2S, 4R)-4-fluoro-L-proline (Fyp); Compound 4: (4,4)-difluoro-L-proline (dFp). b, 
Chemical depiction of cis-trans isomerization of the peptide amide bond containing proline. 
 
Halogen-containing insulins. Protein amyloidogenesis has been implicated in several human 
diseases41, e.g., amyloid precursor protein (APP) in Alzheimer’s Disease (AD) and insulin in 
insulin-derived amyloidogenesis. Recent literature42 has presented biophysical 
characterization of an iodinated-insulin lispro variant in an effort to stabilize insulin and 
prevent fibril formation. Insulin lispro (LysI) was the first RAI to be engineered43 and made 
through mutating ProB28 and LysB29 to LysB28 and ProB29, respectively; these mutations 
increased LysI’s dissociation kinetics but did not result in any additional stability. It was 
speculated that iodination of tyrosine at position 26 of the B chain (TyrB26) to produce 
iodo-TyrB26 insulin lispro (iodo-LysI) could keep the beneficial rapid acting nature of LysI, 
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but also enhance its stability with the placement of a halogenated compound within the 
dimer interface42. Fibrillation and hexamer dissociation kinetic experiments found that iodo-
TyrB26 was marginally able to resist fibril formation but the iodo-LysI hexamer dissociates 
at a rate similar to wild-type insulin (ProI), effectively losing its RAI status, and retains about 
70% of its biological activity. Nonetheless, iodo-LysI is one of the first demonstrations in the 
literature where non-canonical amino acids (ncAAs) are used to modulate the biophysical 
properties of insulin. 
Here, we propose to use fluoroprolines to modulate the biophysical properties of 
insulin. The small size of fluorine should be less of a perturbation than iodine; in addition, 
substitution at B28 is not expected to interfere with biological activity because of its 
distance from important binding residues44. Fluoroprolines have also been studied 
extensively in other contexts (e.g. fluorescent proteins7,45, collagen3,13,23,46,47, DNA 
polymerase48), which can be useful in elucidating the effects of fluorine on insulin. We hope 
the analysis of fluoroinsulins will allow us to further understand the biophysical behavior of 
insulin and as an addition to the insights gained from the hydroxyinsulins in Chapter 2, 
perhaps provide general guidelines for future insulin engineering. 
Results and Discussion 
Recombinant production of biologically active FzpI, FypI and dFpI. It has been reported49 
that Fzp and Fyp can be incorporated into newly synthesized proteins in E. coli using the 
endogenous translational machinery, and dFp can be incorporated with an overexpressed 
prolyl-tRNA synthetase (ProRS) under osmotic stress conditions (NaCl concentration at 300 
mM). Expression of proinsulin (PI) was confirmed via polyacrylamide gel electrophoresis 
 
 50 
(Figure 3.3 b-d). Incorporation levels were assessed using matrix-assisted laser desorption 
ionization mass spectrometry (MALDI-MS; Figure 3.3 e-h) and found to be approximately 
90% by comparing areas of the peaks corresponding to the fluorinated or difluorinated 
peptides at m/z = 1575 Da or 1594 Da, respectively, and the wild-type peptide at m/z = 
1558 Da.  
Figure 3.3 | Insulin expression and incorporation of fluoroprolines 
a, Plasmid pQE80PI-proS containing gene construct proinsulin under inducible lac promoter and an 
overexpressed Ec ProRS for bacterial expression. b-d, SDS-PAGE of cell lysates with lanes labeled for 
pre-induction (PRE) and post-induction in minimal media supplemented with either nothing (19aa), 
Fzp (a), Fyp (b) or dFp (c), or Pro. e-h:  MALDI-MS traces of isolated proinsulin peptide fragment 
46RGFFYTPKTRRE57 obtained by gluC digestion. Peptide fragment masses corresponds to either wild 
type mass 1558 Da (e) or shifted masses 1575 Da if Fzp (f) or Fyp (g), and 1594 Da if dFp (h) is 
incorporated. Inset is whole protein MALDI-MS (instrument error of ~10 Da, 1-2%) with observed 
masses: 5799 Da (e, ProI), 5822 Da (f-g, FzpI and FypI), and 5839 (h, dFpI). All MALDI-MS spectra 




Refolding, and insulin maturation and biological activity. Inclusion bodies containing PI were 
extracted and resolubilized in denaturing buffer prior to purification with Ni-NTA affinity 
chromatography. Elution fractions containing PI were combined, pH-adjusted, and 
subjected to oxidative sulfitolysis, and refolded. The refolded protein was isolated by 
shifting to the solution to acidic conditions and then dialyzed, lyophilized and re-suspended 
in water for proteolytic cleavage (with trypsin and carboxypeptidase B) and liquid 
chromatography (HPLC) purification. Post-HPLC fractions containing mature insulin were 
lyophilized, re-suspended in phosphate buffer prior to verification by whole protein MALDI-
MS (Figure 3.3e-h, insets) and polyacrylamide gel electrophoresis. PI and insulin yields were 
similar to the hydroxyinsulins described in Chapter 2. Insulin fractions were stored at -80°C 
and thawed on ice prior to use. 
We expected our recombinant insulins to be biologically active because the modified 
residue B28 or nearby residues (B27, B29-B30) are not involved in binding to the insulin 
receptor (IR)50. Recombinant insulins formulated under pharmaceutical conditions were 
injected into streptozocin (STZ)-induced diabetic mice and able to lower blood glucose 
levels within 30 minutes (Figure 3.4a).  
Incorporation of fluoro-prolines alters insulin dimerization. At 60 µM, in absence of Zn2+ and 
phenol, both FypI and dFp appears to be monomeric (with CD spectra nearly identical to 
that of AspI; Figure 3.4b) while the spectrum of FzpI suggests a dimeric insulin (with CD 




Figure 3.4 | Fluorination at ProB28 does not affect biological activity but alters insulin 
dimerization, dissociation kinetics, and stability 
a, Reduction of blood glucose following subcutaneous injection of 35 μg/kg insulins into streptozocin-
induced diabetic mice. Glucose levels were measured post-injection via tail vein sampling. ProI, 10% 
ProI, FzpI, FypI, dFpI or vector were formulated as described42. Error bars denote one standard 
deviation (n ≥ 3). b, Far UV CD spectra collected on 60 μM insulins in 10 mM phosphate buffer, pH 
8.0 at 25°C. c, Insulin hexamer dissociation following sequestration of Zn2+ by terpyridine.  Zn2+-(terpy) 
signal was monitored at 334 nm and fitted to a mono-exponential decay. FzpI, FypI and dFpI contain 
10% ProI. The curves for the pairs: FypI and AspI, FzpI and ProI, are indistinguishable in this plot. d, 
Representative fibrillation curves for 60 µM insulins (37°C, 960 RPM; n=4). Insulin fibrils were 
detected by the rise in Thioflavin T (ThT) fluorescence that occurs upon binding to fibrillar aggregates. 
Median curves are shown for ProI, AspI and HzpI. 
 
To obtain estimates for the insulin dimer’s dissociation constant (KD)51, we obtained 
CD spectra at varying concentrations (Figure 3.5). FzpI has a KD of approximately 2 µM, 
which is on the same order of magnitude as ProI, indicating that the (4S)-fluoro group of 
FzpB28 does not substantially affect dimerization.  Both FypI and dFpI have a KD of 
approximately 150 μM, indicating a perturbed dimer interface and are more monomeric 
than FzpI and ProI. The stereochemical trend for dimerization correlate for the mono-
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fluoroinsulins and hydroxyinsulins: (4S)-substituents have little effect on the dimerization 
constant (KD ~10 µM), while the (4R)-substituents results in a significantly perturbed dimer 
interface (KD >100 µM). 
Figure 3.5 | Far UV CD spectra of fluoroinsulins at varying concentrations. 
ProI (a), FzpI (b), FypI (c), and dFpI (d) in 10 mM phosphate buffer, pH 8.0 at 25°C. 
 
Hexameric FypI behaves like an RAI. Previous studies of RAIs have shown that 
destabilization of the dimer interface correlates with accelerated dissociation of the 
hexamer and rapid onset of insulin action52,53. Triggered dissociation of Zn2+-hexamers by 
addition of the chelating agent terpyridine54 (Figure 3.4c) revealed nearly identical rates of 
dissociation for FzpI and ProI, (𝜏1/2 = 98.3 ± 5.5 s and 90.4 ± 4.2 s, respectively), and for FypI 
and AspI (𝜏1/2 = 40.0 ± 4.1 s and 42.7 ± 4.3 s, respectively). dFpI exhibited hexamer 
dissociation kinetics (𝜏1/2 = 67.1 ± 4.3s) between those of ProI (and FzpI) and AspI (and FypI); 
the intermediate 𝜏1/2 for dFpI suggests that the two fluoro-stereoisomers may have 
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opposing effects on hexamer dissociation rates. It should be noted that the rate of hexamer 
dissociation for the fluoroinsulins roughly correlates with KD, aligning with previous studies 
performed on RAIs and in contrast with the results for the hydroxyinsulins (Chapter 2). 
Fluorinated insulins fibrillate faster than (4S)-hydroxyinsulin. Given the abundance of 
literature detailing stabilizing effects due to fluorination in proteins19,55,56, and the discovery 
of HzpI (Chapter 2) with enhanced resistance (~3-fold) against fibril formation, we 
speculated that fluorination at the proline could have similar results. Each of the 
fluoroinsulins was subjected to fibrillation lag time analysis (Figure 3.4d).  We found that 
the orientation of the fluorine at position B28 did influence fibrillation time lag, but none of 
the effects were as striking as HzpI (Figure 3.4d; dotted grey line). In the case study for β2m, 
Fzp-β2m was found to be the most stable variant due to Fzp’s Ktrans/cis of 2.5. When Pro32 is 
in its cis form, β2m is more resistant to fibril formation; however, this explanation does not 
suffice for insulin because the mechanism for insulin fibrillation does not depend on the cis 
orientation of ProB28 (Figure 3.6). The hypothesis for insulin fibrillation57-62 is that two key 
segments63 (13LYQLEN18 of the A chain and 12VEALYL17 of the B chain) when unfolded and 
exposed are responsible for the formation and growth of insulin fibrils (Figure 3.6). These 
two key segments are buried and unexposed when insulin is dimeric, leading to the 
hypothesis that the insulin dimer is more stable than the monomer.  This assumption is 
further corroborated in the literature by experimental evidence that a covalently-linked, 





Figure 3.6 | Fibril forming segments and hypothesis for insulin fibrillation. 
 a, Pictorial representation of mature insulin residues with fibril-forming segments colored in red (A 
chain) and blue (B chain). b, Hypothesis for insulin fibrillation. Schematic expanded from figure 
previously described65. 
 
In Chapter 2, we speculated that the hydroxyl group of HzpB28 strengthens the 
dimer state through hydrogen bonding (Figure 2.8) and prevents the C-terminus of the B 
chain from fraying and hence, delaying fibrillation. Fluorine cannot form hydrogen bonds in 
the same manner as a hydroxyl group. Therefore, we suspect that the slight increase in 
fibrillation lag time for FzpI and dFpI, compared to ProI and AspI, may arise from the 
network of hydrophobic interactions66 in the dimer interface (formed by the side chains of 
residues at positions B16, B24-25, B28 and others).  
To help us further understand the atomistic interactions that are causing the 
biophysical behavior of the fluoroinsulins, we obtained crystal structures of all three 
variants (FzpI, FypI, and dFpI).  
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Figure 3.7 | Crystal structures of FzpI, FypI, and dFpI. 
In top panels (a, b, c), insulins from PDB in the T2 dimer (a) and R6 hexamer (b, c) forms. In bottom 
panels (d, e, f), structures of fluoro-insulins in T2 dimer (d) and R6 hexamer (e, f).  All images, except 
(c), highlight the distance between the 4th-carbon or its substitution group of the prolyl ring at 
position B28 and its closest neighbors, backbone carbonyl oxygen atoms of GlyB20’ and GluB21. For 
AspI (c), the distances highlighted are between the backbone carbonyl oxygen atoms of GlyB20’ and 
GluB21, and the closest oxygen atom from AspB28. 
 
Crystal structures reveal endo/exo conformations of the fluorinated prolyl ring. Solved 
crystal structures for fluoroinsulins, in comparison with ProI, display overall backbone root-
mean-square-deviation (RMSD) values of 0.41 Å (R6- FzpI), 0.39 Å (T2- FypI), and 0.58 Å (R6- 
dFpI)67. The overall crystal structures of R6-FzpI and R6-dFpI are similar to R6-ProI; the prolyl 
rings at both FzpB28 (Figure 3.7e) and dFpB28 display (Figure 3.7f) the typical endo 
conformation seen at ProB28 (Figure 3.7ab). This structural similarity is expected for FzpI 
and ProI, due to their similar KD values, hexamer dissociation kinetics, and fibrillation lag 
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times, but not for dFpI, whose biophysical characteristic values (Table 3.1) are intermediate 
between ProI (and FzpI), and AspI (and FypI). 
Table 3.1 | Biophysical characteristics of fluoroinsulins. 
Errors are given as one standard deviation (n ≥ 4). *Quantified by MALDI-MS on proinsulin peptide 
obtained by gluC digestion: 46RGFFYTPKTRRE57. Samples were prepared from combining 5-1L shake 










Lag Time (h) 
KD dimer 
(µM) 
L-Proline -- ProI 90.4 ± 4.2 5.1 ± 1.5 9 μM68 
Fzp 97 FzpI 98.3 ± 5.5 8.4 ± 1.2 ~2 μM  
Fyp 96 FypI 40.0 ± 4.1 2.6 ± 0.3 ~150 μM 
dFp 86 dFpI 67.1 ± 4.3 9.0 ± 0.5 ~150 μM 
L-Aspartic acid -- AspI 42.7 ± 4.3 5.3 ± 1.0 >500 μM69 
  
One striking revelation of the solved fluoroinsulin structures is that, in the crystal 
structure of T2-FypI (Figure 3.7d), FypB28’s prolyl ring is in the exo conformation, which has 
yet to be seen in any crystal structures of insulin.  The expected conformation for the prolyl 
ring at position B28 is the endo conformation (Figure 2.7, Figure 2.8 and Figure 3.7abef). An 
exo conformation of the prolyl ring results in a significant perturbation (from endo), causing 
both the γ-carbon and (4R)-fluorine of FypB28 to be further away from its nearest backbone 
neighbors (GluB21′ and GlyB20′) compared to T2-ProI (Figure 3.7a), which may account for 
FypI’s RAI-like behavior, and with similar distances measured in the structure of R6-AspI70 
(Figure 3.7c). Although we were unable to obtain crystal structures of R6-FypI to directly 
compare FypI to R6-ProI and R6-AspI, this exo conformation should also be present in the 
FypI hexamer, as the endo conformation for ProI is present in both its T2 dimer and R6 
hexamer forms.  
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Figure 3.8 | Van der Waals contacts within dimer interface for fluoroinsulins. 
In top panels (a, b, c), images of T2 insulins highlighting vdW contact partners for γ-carbon of the 
prolyl ring at position B28 (a, b) or fluorine at the 4th position (c). In bottom panels (d, e, f), images 
R6 insulins highlighting vdW contact partners for carbons (α, β, γ, and δ) of the prolyl ring at position 
B28 (d, e, f) and fluorine at the 4th position (e, f). vdW contacts are represented by teal lines. 
 
Crystal structures of fluorinated insulins reveal new van der Waals contacts. Hydrogen 
bonding interactions between backbone atoms from residues B24-B26 on the antiparallel β-
strands of each insulin monomer66 are the driving forces for dimerization of the insulin 
monomer. Dimerization is also aided by hydrophobic interactions between the β-turns 
(residues B20-23)68 and C-terminal residues B27-29 of each insulin monomer69. We used 
crystallography software to determine the location of van der Waals (vdW) contacts71 
between the γ-carbon and fluorine group at position B28 and residues in the dimer 
interface. The prolyl ring of ProB28 in both the T2 and R6 structures form vdW contacts 
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primarily with residues GluB21′ and GlyB20′ of the interacting insulin monomer across the 
dimer interface (Figure 3.8ad, contacts for γ-carbon are shown). The vdW contacts for γ-
carbon and (4S)-fluorine of FzpB28 in the R6-FzpI structure are also primarily with GluB21′ 
and GlyB20′ (Figure 3.8e). The similar vdW contacts for R6-ProI and R6-FzpI are reflected in 
the biophysical properties, as FzpI has a dimerization constant similar to that of ProI and 
dissociates from its hexamer form at a rate indistinguishable from that of ProI. FzpI contains 
additional vdW contacts made by the (4S)-fluorine of FzpB28 to GluB21′ and GlyB20′ (Figure 
3.8e), which may be reflected in the aggregation data (Figure 3.4d) as FzpI has a slightly 
delayed fibrillation lag time compared to ProI. Like R6-FzpI, the γ-carbon and the (4S)-
fluorine of dFpB28 contacts GluB21′ and GlyB20′ across the dimer interface, and the 
biophysical data of dFpI roughly correlates with these interactions, as its dimerization 
constant and hexamer dissociation rate fall between values for FzpI and ProI, and AspI, with 
a fibrillation lag time that indistinguishable from that of FzpI.  
The (4R)-fluorine of dFpB28 also interacts with TyrB26 on the same B chain (Figure 
3.8f); since this interaction is not present in R6-FzpI, we theorize it may be responsible for 
the enhanced hexamer dissociation rate of dFpI compared to FzpI and ProI. Unfortunately, 
it is difficult to form any conclusions regarding the atomistic differences that may be 
responsible for the (lessened) propensity to fibrillate for FzpI and dFpI because we were 
unable to obtain crystal structures in the T form. However, we can speculate from the R6 
structures that the increase in stability for FzpI and dFpI may be due to the additional 
contacts across the dimer interface (with GluB21′ and GlyB20′) and with TyrB26 (Figure 
3.8def), compared to R6-ProI. 
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Figure 3.9 | CH-π interaction between ProB28 and TyrB26. 
Criteria for CH/π in the literature are assessed by: (dC and θ)72 or (dC, θ, and ψ)73,74; the latter being 
more conservative but can exclude weaker CH/π interactions. Geometries of CH-π interactions 
between ∂-carbon of ProB28 and the centroid of the benzene ring of TyrB26 for in an ideal orientation 
(left), T2-ProI (a, b), and T2-FypI (c, d).  
 
The (4R)-fluorine and γ-carbon at position B28 primarily interacts with the aromatic 
ring of TyrB26 in the T2-FypI structure (Figure 3.8bc); FypB28 does not contact any residues 
across the dimer interface (residues B20′ to B29′). Both computational73 and 
experimental75,76 evidence in the literature suggests the hydrogen from CH bonds of proline 
can interact favorably with the π-component of aromatic amino acids. The geometric 
orientation between (4R)-fluorine of FypB28 and the aromatic ring of TyrB26 is more 
indicative of a destabilizing interaction77 because, not only is fluorine unable to form a CH/π 
interaction78 but, the (4R)-fluorine of FypB28 may also replace a potential CH/π interaction 
present in the wild-type structure (Figure 3.9ab). From these observations, we hypothesize 
that the lack of vdW contacts in FypI’s dimer interface, the presence79 of (4R)-fluorine, and 
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absence of a CH/π interaction with TyrB26, through replacement of hydrogen at the γ-
carbon of the B28 prolyl ring by (4R)-fluorine, may result in a destabilized dimer, faster 
hexamer dissociation kinetics, and an increased propensity to fibrillate. 
Figure 3.10 | Crystal structures of halogenated insulins with vdW contacts with A chain. 
In top panels (a, b), T2 insulins highlighting vdW contact partners for γ-carbon of the prolyl ring at 
position B28 (a, b) or fluorine at the 4th position (b). In bottom panels (c, d), R6 insulins highlighting 
vdW contact partners for γ-carbon of the prolyl ring at position B28 (c, d) and iodine at the 3rd position 
of TyrB26 (d). vdW contacts are represented by solid teal lines. 
 
 Halogen-based medicinal chemistry has been successful for pharmaceutical research 
and development, and there is much interest in extending this technology for engineering  
therapeutic proteins80. As protein engineers, corroborating information in the literature can 
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give significance to certain interactions that might seem minor in a single study. An example 
is the vdW contact between a halogen and residue ValA3; this interaction is present in both 
T2-Fyp and the crystal structure of (3-Iodo-Tyr)-ProI in the R6 hexamer state.  
Through ncAA mutagenesis at ProB28 of insulin, we have obtained a greater understanding 
of the molecular interactions responsible for the tradeoffs exhibited between stability and 
hexamer dissociation rates for insulin. The information revealed by our fluorinated insulins 
provide further confirmation of the importance of hydrophobic interactions between 
residues along the dimer interface and its effects on biophysical properties such as 
dimerization, dissociation kinetics, and stability. We suggest that the placement of (4R)-
fluorine of FypB28 near the aromatic ring of TyrB26 may be destabilizing and thereby, 
increases both the rate of disassembly and fibril formation. A facile strategy to perform 
atom-by-atom perturbations would be to use ncAA mutagenesis at either or both B26 or 
B28 positons to selectively strengthen CH/π interactions (e.g. through conversion to polar/π 
or cation/π interactions).  For example, the use of a fluorinated aromatic amino acid81,82 at 
position B26 would enhance the π-component of the aromatic ring or a more polar or 
positively-charged (R)-substituent at either or both the γ- or δ-carbon of positon B28 to 
obtain a stronger CH/π or cation-π interaction83. The use of ncAA mutagenesis in proteins is 
akin to the use of medicinal chemistry on small molecules, which has been the driving force 
for pharmaceutical research and development in the past century. Perhaps, as the push for 
more biologics to be available on the market increases, ncAA mutagenesis will prove to be a 
useful tool for performing medicinal chemistry on proteins. 
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Materials and Methods 
Materials. All canonical amino acids and protected Boc-(4,4)-difluoro-L-proline were 
purchased from Sigma.  (4S)-fluoro-L-proline (Hzp) and (4R)-fluoro-L-proline (Fyp) was 
purchased from Bachem Americas. All solutions and buffers were made using double-
distilled water (ddH2O).  
Strains and plasmids. The proinsulin (PI) gene with an N-terminal hexa-histidine tag (6xHIS), 
and flanked by EcoR1 and BamH1 cut sites was ordered as a gBlock (Integrated DNA 
Technologies). Both the gBlock and vector pQE80L for IPTG-inducible expression were 
digested with EcoRI and BamHI.  Linearized vector pQE80L was dephosphorylated by 
alkaline phosphatase (NEB). Ligation of the digested PI gene and linearized vector yielded 
plasmid pQE80PI (to produce ProI). To make plasmid pQE80PI-proS (to produce FzpI, FypI 
and dFpI): Genomic DNA was extracted from E. coli strain DH10β using DNeasy Blood and 
Tissue Kit (Qiagen). Primers (Integrated DNA Technologies) were designed to amplify the E. 
coli proS gene, encoding prolyl-tRNA synthetase, under constitutive control of its 
endogenous promoter, from purified genomic DNA, and to append NheI and NcoI sites. The 
digested proS gene was then inserted into pQE80PI between transcription termination sites 
by ligation at NheI and NcoI restriction sites. Proline-auxotrophic E. coli strain CAG18515 
was obtained from the Coli Genetic Stock Center at Yale University. Prototrophic E. coli 
strain BL-21 was used for rich media expression of canonical insulins (ProI, AspI). Site-
directed mutagenesis of pQE80PI at B28 was performed to make plasmid pQE80PI-asp, 
which differs from pQE80PI by three nucleotides that specify a single amino acid mutation 
to aspartic acid. All genes and plasmids were confirmed by DNA sequencing.   
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Protein expression. Plasmids pQE80PI and pQE80PI-asp were transformed into BL21 cells 
and grown on ampicillin-selective agar plates. A single colony was used to inoculate 5 mL of 
Luria-Bertani (LB) medium and grown overnight; the resulting saturated culture was used to 
inoculate another 1 L of LB medium. All expression experiments were conducted at 37°C, 
200 RPM in shake flasks (Fernbach 2.8 L flasks, Pyrex®). Each culture was induced with 1 
mM IPTG at mid-exponential phase (OD600 ~0.8). For incorporation of fluoroprolines (Fzp, 
Fyp and dFp), pQE80PI-proS was transformed into CAG18515 cells, which were grown on 
ampicillin-selective agar plates. To facilitate growth, a single colony was used to inoculate 
25 mL of LB medium and the culture was grown overnight prior to dilution into 1 L of 1X 
M9, 20 aa medium (8.5 mM NaCl, 18.7 mM NH4Cl, 22 mM KH2PO4, 47.8 mM Na2HPO4, 0.1 
mM CaCl2, 1 mM MgSO4, 3 mg/L FeSO4, 1 μg/L of trace metals (Cu2+, Mn2+, Zn2+, MoO42-), 35 
mg/L thiamine hydrochloride, 10 mg/L biotin, 20 mM D-glucose, 200 mg/L ampicillin with 50 
mg/L of L-amino acids, each). At an appropriate cell density (OD600 ~0.8), the culture was 
subjected to a medium shift; briefly, cells were centrifuged and washed with saline prior to 
resuspension into 0.8 L of 1.25X M9, 19 aa (1X M9, 20 aa medium without L-proline). After 
cells were further incubated for 30 min to deplete intracellular proline, 200 mL of 5X 
additives (1.5 M NaCl, 2.5 mM Fzp or Fzp, or 5mM dFp) was added to the culture. After 
another 15 min of incubation at 37°C to allow amino acid uptake prior to induction, IPTG 
was added to a final concentration of 1 mM. At the end of 2 h, cells were harvested by 
centrifugation and stored at -80°C until further use.  
Cell lysis and refolding from inclusion bodies. Cells were thawed on the benchtop for 15 min 
prior to resuspension in lysis buffer (B-PER®, 0.5 mg/mL lysozyme, 50 U/mL benzonase 
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nuclease). Cells were gently agitated at RT for 1 h prior to centrifugation (10 000 g, 10 min, 
RT); supernatant was discarded and the pellet was washed thrice: once with wash buffer (2 
M urea, 20 mM Tris, 1% Triton X-100, pH 8.0) and twice with sterile ddH2O; centrifugation 
followed each wash and the supernatant was discarded. The final washed pellet containing 
inclusion bodies (IBs, ~50% PI) was re-suspended in Ni-NTA binding buffer (8 M urea, 300 
mM NaCl, 50 mM NaH2PO4, pH 8.0) overnight at 4°C or at RT for 2 h, both with gentle 
agitation. The suspension was centrifuged to remove insoluble debris; the remaining pellet 
was discarded and the supernatant was mixed with pre-equilibrated Ni-NTA resin (Qiagen) 
at RT for 1 h in order to purify PI from the IB fraction. Unbound proteins in the IB fraction 
were collected in the flow-through (FT), and the resin was washed with Ni-NTA wash buffer 
(8 M urea, 20 mM Tris base, 5 mM imidazole, pH 8.0) and Ni-NTA rinse buffer (8 M urea, 20 
mM Tris base, pH 8.0) prior to stripping PI from the resin with Ni-NTA elution buffer (8 M 
urea, 20 mM Tris base, pH 3.0).  Fractions (IBs, FT, W, elution) were collected and run under 
reducing conditions on SDS-PAGE (Bis/Tris gels, Novex®); elution fractions containing PI 
were pooled and solution pH was adjusted to 9.6 with 6 N NaOH in preparation for 
oxidative sulfitolysis. Oxidative sulfitolysis was performed at RT for 4 h, with the addition of 
sodium sulfite and sodium tetrathionate (0.2 M Na2SO3, 0.02 M Na2S4O6); the reaction was 
quenched by 10-fold dilution with ddH2O. To isolate PI from the quenched solution, the pH 
was adjusted to between 3.5 and 4.5 by adding 6 N HCl dropwise; the solution became 
cloudy. The solution was centrifuged (10 000 g, 10 min, RT) and supernatant discarded. The 
PI pellet was then re-suspended in refolding buffer (0.3 M urea, 50 mM glycine, pH 10.6) 
and protein concentration was estimated by the bicinchoninic acid assay (BCA assay, 
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Pierce®). The concentration of PI was adjusted to 0.5 mg/mL. Refolding was initiated by 
addition of β-mercaptoethanol to a final concentration of 0.5 mM and allowed to proceed 
at 12°C overnight with gentle agitation (New Brunswick® shaker, 100 RPM). Post-refolding, 
soluble PI was harvested by adjusting the pH of the solution to 4-5 by dropwise addition of 6 
N HCl and by high speed centrifugation to remove insoluble proteins. The supernatant was 
adjusted to pH 8-8.5 by dropwise addition of 6 N NaOH and dialyzed against fresh PI dialysis 
buffer (7.5 mM sodium phosphate buffer, pH 8.0) at 4°C with five buffer changes to remove 
urea. The retentate (PI in dialysis buffer) was then lyophilized and subsequently stored at -
80°C until further processing. Typical yields were 25-50 mg PI per L of culture (25-30 mg/L 
for non-canonical PI, 40-50 mg/L for canonical PI expression in rich media) 
Proteolysis and chromatographic (HPLC) purification. The dry PI powder was re-dissolved in 
water to a final concentration of 5 mg/mL PI (final concentration of sodium phosphate 
buffer is 100 mM, pH 8.0). Trypsin (Sigma-Aldrich) and carboxypeptidase-B (Worthington 
Biochemical) were added to final concentrations of 20 U/mL and 10 U/mL, respectively to 
initiate proteolytic cleavage. The PI/protease solution was incubated at 37°C for 2.5 h; 
proteolysis was quenched by addition of 0.1% trifluoroacetic acid (TFA) and dilute HCl to 
adjust the pH to 4. Matured insulin was purified by reversed phase high-performance liquid 
chromatography (HPLC) on a C18 column using a gradient mobile phase of 0.1% TFA in water 
(solvent, A) and 0.1% TFA in acetonitrile (ACN; solvent, B). Elution was carried from 0% B to 
39% B with a gradient of 0.25% B per minute during peak elution. Fractions were collected 
and lyophilized, and the dry powder was re-suspended into 10 mM sodium phosphate, pH 
8.0. Insulin-containing fractions were verified by matrix-assisted laser 
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desorption/ionization-mass spectrometry (MALDI-MS; Voyager MALDI-TOF, Applied 
Biosystems) and SDS-PAGE to ensure identify and purity. Typical yields were 5-10 mg insulin 
per 100 mg PI (FzpI and FypI ~10mg end, dFpI on ~5mg end). Fractions were stored at -80°C 
in 10 mM phosphate buffer, pH 8.0 until further use. 
Verification of dFp, Fyp and Fzp incorporation levels and maturation.  A 30 μL aliquot of PI 
solution (8 M urea, 20 mM Tris, pH 8) was subjected to cysteine reduction and alkylation (5 
mM DTT, 55°C, 20 min; 15 mM iodoacetamide, RT, 15 min, dark) prior to 10-fold dilution 
into 100 mM NH4HCO3, pH 8.0 (100 μL final volume).  Peptide digestion was initiated with 
0.6 μL of gluC stock solution (reconstituted at 0.5 μg/μL with ddH2O, Promega) at 37°C for 
2.5 h.  The reaction was quenched by adding 10 μL of 5% TFA and immediately subjected to 
C18 ZipTip (Millipore) peptide purification and desalting according to the manufacturer’s 
protocol.  Peptides were eluted in 50% ACN, 0.1% TFA; the eluent was then diluted three-
fold into matrix solution (saturated α-cyanohydroxycinnamic acid in 50% ACN, 0.1% TFA) 
and analyzed by mass spectrometry (Voyager MALDI-TOF, Applied Biosystems).  
Incorporation levels were analyzed prior to and after refolding; incorporation percentage 
was calculated by comparing total AUC (area under the curve, arbitrary units) of the non-
canonical peak (1575 Da for the proinsulin peptide containing FzpB28 or FypB28 or 1594 Da 
if dFpB28, ~5825 Da for intact FzpI and FypI or ~5840 Da for dFpI) with total AUC of its wild-
type counterpart (1557 Da and 5808 Da, respectively). Maturation of FzpI, FypI, and dFpI 
was analyzed after HPLC purification. TFA (1.6 μL, 5%) was added to 15 μL mature insulin 
solution (10 mM phosphate buffer pH 8.0) and subjected to C18 ZipTip (Millipore) peptide 
purification and desalting per the manufacturer’s protocol.  
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Reduction of blood glucose in diabetic animals. NODscid (NOD.CB17-Prkdcscid/J) mice were 
obtained from Jax Mice (Bar Harbor, Maine). Mice were maintained under specific 
pathogen-free conditions, and experiments were conducted according to procedures 
approved by the Institutional Animal Care and Use Committee at the City of Hope. Adult (8- 
to 12-week-old) male NODscid mice were injected intraperitoneally (50 mg/kg/day for 3 
consecutive days) with freshly prepared streptozotocin (STZ) in 0.05 M citrate buffer, pH 4.5 
to induce diabetes. Diabetes was confirmed 3 weeks after the last dose of STZ by detection 
of high glucose levels (defined as >200 mg/dL), measured by using a glucomonitor 
(FreeStyle; Abbott Diabetes Care, Alameda, CA) in blood (10 μL) sampled from the lateral 
tail vein. Insulin analogs concentrations were determined from A280 measurements using a 
molar extinction coefficient of 6080 M-1 cm-1 and diluted to 100 µg/mL into a formulation 
buffer according to a previous report84. Insulin analogs in solution were injected 
subcutaneously at the scruff and blood glucose was measured at the indicated time points. 
Circular Dichroism. Spectra were collected in a 1 cm quartz cuvette in 10 mM sodium 
phosphate buffer pH 8.0. Data were collected from 195 nm to 250 nm, with step size of 0.25 
nm and averaging time of 1 s on a Model 410 Aviv Circular Dichroism Spectrophotometer; 
spectra were averaged over 3 repeat scans. A reference buffer spectrum was subtracted 
from the sample spectra for conversion to mean residue ellipticity. Insulin concentrations 
ranged from 3 µM to 200 µM. 
Hexamer Dissociation Assay. Insulins were quantified by both UV absorbance (NanoDrop 
Lite, ThermoFisher) and BCA assay, and normalized to 125 μM insulin prior to dialysis 
against 50 mM Tris/perchlorate, 25 μM zinc sulfate, pH 8.0 overnight at 4°C using a D-tube 
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dialyzer (Millipore Corp.) with MWCO of 3.5 kDa.  Aliquots of dialyzed insulin solution were 
mixed with phenol to yield samples of the following composition: 100 μM insulin, 20 μM 
zinc sulfate, 100 mM phenol. Dissociation was initiated by addition of terpyridine (Sigma-
Aldrich) to a final concentration of 0.3 mM from a 0.75 mM stock solution. A Varioskan 
multimode plate reader (ThermoScientific) was used to monitor absorbance at 334 nm. 
Kinetic runs were done at least in triplicate, and the data were fit to a mono-exponential 
function using Origin software.  Post assay insulin samples were pooled and sample quality 
was determined by SDS-PAGE. 
Fibrillation Assay.  Insulin samples (60 μM in 10 mM phosphate, pH 8.0) were centrifuged at 
22 000 g for 1 h immediately after addition of thioflavin T (ThT) (EMD Millipore) to a final 
concentration of 1 μM.  Samples were continuously shaken at 960 RPM on a Varioskan 
multimode plate reader at 37°C, and fluorescence readings were recorded every 15 min or 
20 min for 48 h (excitation 444 nm, emission 485 nm).  Assays were run in quadruplicate, in 
volumes of 200 μL in sealed (Perkin-Elmer), black, clear-bottom 96 well plates (Grenier 
BioOne). 
Crystallographic Studies. Insulin crystals were obtained from sitting drop trays set using a 
Mosquito robot (TTP Labtech). Drops were set by mixing 0.4 μL insulin solution with 0.4 μL 
well solution. Cells were cryoprotected in a mother liquor containing 30% glycerol prior to 
looping and flash freezing in liquid nitrogen. Data were collected at SSRL beamline BL12-2 
using a DECTRIS PILATUS 6M pixel detector. Initial indexing and scaling was performed with 
XDS; for some structures, data were re-scaled in alternative space groups using Aimless85. 
Initial phases were generated by molecular replacement in PHASER with 3T2A (5UOZ) or 
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1EV3 (5UQA and 5UU3)86. Structure refinement was carried out in Coot and Refmac587,88. 
Data were deposited in the PDB with the following codes: 5UQA (R6-FzpI), 5UOZ (T2-FypI), 
5UU3 (R6-dFpI). All distances and contacts were computed using UCSF Chimera 
Crystallography Software. 
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Chapter 4  – Understanding the effects of 









Insulin is known to be sensitive to mutation of the proline residue at position 281,2 of the 
insulin B-chain (ProB28). Rapid-acting insulins (RAIs) have taken advantage of this mutation 
to disrupt the inter-dimer interface and enhance the rate of disassembly from the insulin 
hexamer, but remain susceptible to fibrillation. Here we show that further replacement of 
ProB28 with proline analogs of changing ring composition results in minor perturbations 
structurally but can lead to large changes in insulin stability and disassembly. The changes in 
biophysical properties of insulin resulting from the removal, replacement or addition of 
carbon and hydrogen atoms at ProB28 demonstrates that it is possible to specifically 





Prolyl ring. The uniqueness of proline primarily stems from the 5-membered prolyl ring, 
which is the result of the covalent bond between the nitrogen atom of the backbone and 
the α-carbon. Proline’s restricted backbone limits accessible dihedral angles; thus, proline is 
found most often in β-turns and at the ends of α-helices3. Bioinformatic analysis have also 
revealed that proline residues are frequently found in repeating motifs that have diverse 
and critical functions biologically4. The restricted torsion angles and ring shape of the amino 
acid often introduce a “kink”5 in the protein structure that can have dynamic and 
biologically relevant consequences.  For example, it has been demonstrated in the literature 
that proline acts as a switch in transmembrane receptors6 for initiating signaling pathways. 
Figure 4.1 | Proline analogs for study of altered ring composition. 
Compound 1: L-proline; Compound 2: (S)-azetidine-2-carboxylic acid (Aze); Compound 3: (3,4)-
dehydro-L-proline (Dhp); Compound 4: (1,3)-thiazolidine-4-carboxylic acid (Thz); Compound 5: (S)-
piperidine-2-carboxylic acid (Pip). 
 
Protein engineering with proline analogs of varied ring composition.  A significant body of 
work examines proline analogs, a small subset7-11 of which have explored modifications to 
the prolyl ring. Initial studies on proline analogs of altered ring composition involved 
understanding the mechanisms governing their cis-trans isomerization preferences12,13; 
later, studies were expanded to the replacement of proline residues in proteins to 
understand the effects of cis-trans isomerization on protein properties.  
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Collagen. In addition to research on hydroxy- and fluoro-prolines, the presence of (S)-
azetidine-2-carboxylic acid (Aze) in place of proline in collagen has also been studied 
extensively14,15. Evolutionary theories16 have postulated that Pro was adapted as one of the 
twenty canonical amino acids (cAA) instead of the 4-membered Aze or the 6-membered (S)-
piperidine-2-carboxylic acid (Pip), due to the more favorable backbone geometry resulting 
from a 5-membered ring. Consistent with such theories, replacing Pro with Aze in collagen 
led to detrimental stability effects and decreased activity15. 
Annexin V. One of the first detailed studies involving (1,3)-thiazolidine-4-carboxylic acid 
(Thz)11 was done in the human protein annexin V, an anticoagulant17, through residue-
specific replacement of Pro. NMR spectroscopy of a Thz-containing peptide determined that 
Thz prefers the cis-amide (Ktrans/cis of 2.8) peptide bond18 about 2-fold more than L-proline 
(Pro). Given that Thz (with similar bond lengths and angles to Pro) is considered to be 
isosteric to Pro, it is not surprising that the secondary structure and thermodynamic 
properties of Thz-annexin V are roughly unchanged compared to its wild-type protein11.  
Proteins with a C-terminal SsrA tag. The “unpuckered” proline analog (3,4)-dehydro-L-
proline (Dhp)19, Aze, and Thz were all incorporated into the model protein YbeL to assess 
the effects of proline analogs on protein degradation through SsrA tagging10. The exact 
function of YbeL is unknown. SsrA appends a peptide sequence (called the SsrA tag, which is 
recognized by multiple endogenous proteases) at the C-terminus to mark a protein for 
degradation20. The last four residues (prior to the stop codon) for YbeL contain two Pro 
residues. It was found that SsrA tagging is sensitive to the identity of the second last Pro 
residue in YbeL, where the tagging rate decreases in the order of: Dhp, Pro, Thz, and Aze; 
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however, the authors could not rationalize the underlying mechanisms for the tagging by 
SsrA with the composition of the proline analog-containing YbeL10. 
 The analogs shown in Figure 4.1 are nonpolar and cannot form hydrogen bonds, and 
have been previously used as probes for understanding the role of proline residues in 
proteins. Thus, we propose to incorporate proline analogs with different prolyl ring sizes to 
modulate the biophysical properties of insulin and further investigate the nonpolar 
interactions present in the insulin dimer interface.  
Results and Discussion 
Recombinant production of AzeI, DhpI, ThzI and PipI. It has been reported21 that Aze, Dhp, 
and Thz can be incorporated into newly synthesized proteins in E. coli using an 
overexpressed prolyl-tRNA synthetase (ProRS) under osmotic stress conditions, and Pip can 
be incorporated using a mutant ProRS (C443G). Incorporations were done using proline-
auxotrophic E. coli strain CAG18515 for Aze and Pip, and KS32 for Dhp, Thz. The KS32 strain 
is the proline-auxotrophic version of parent strain JT3122, which is deficient for proline 
dehydrogenase, that cannot metabolize Dhp and Thz23 or synthesize Pro endogenously. 
Expression of PI was confirmed via polyacrylamide gel electrophoresis (Figure 4.2b-f). 
Incorporation levels (Table 4.1) were assessed using matrix-assisted laser desorption 
ionization mass spectrometry (MALDI-MS; Figure 4.2f-j) and found to be approximately 90% 
by comparing the areas of the peaks corresponding to the non-canonical peptide relative to 
the wild-type peptide. Similarly, post-HPLC fractions containing mature insulin were verified 
by whole protein MALDI-MS (Figure 4.2 f-j, insets). PI and insulin yields were similar to the 
hydroxy- and fluoroinsulins described in Chapters 2-3.  
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Figure 4.2 | Insulin expression and incorporation of prolines analogs of changing ring size. 
a, Plasmid pQE80PI-proS containing gene construct proinsulin under inducible lac promoter and an 
overexpressed Ec ProRS for bacterial expression. b-e, SDS-PAGE of cell lysates with lanes labeled for 
pre-induction (PRE) and post-induction in minimal media supplemented with either nothing (19aa), 
Aze (b), Dhp (c), Thz (d) or Pip (e), or Pro at 0.5 mM. f-j:  MALDI-MS traces of isolated proinsulin 
peptide fragment 46RGFFYTPKTRRE57 obtained by gluC digestion. Peptide fragment masses 
corresponds to either wild type mass 1558 Da (f) or shifted masses if ncPro is incorporated (g, 1544 
for Aze; h, 1555 Da for Dhp; i, 1575 Da for Thz; j, 1571 for Pip). Inset is whole protein MALDI-MS with 
observed masses: 5799 Da (f, ProI), 5789 Da (g, AzeI), 5800 Da (h, DhpI), 5823 Da (i, ThzI) and 5812 
Da (j, PipI). All intact MALDI-MS spectra give experimental masses within error range (~10 Da or 1-




Changing ring compositions at B28 does not result in a destabilized insulin dimer. In the 
absence of Zn2+ and phenolic preservatives, ProI dimerizes with a dissociation constant (KD) 
of approximately 10 µM. Monomeric forms of insulin give rise to characteristic circular 
dichroism (CD) spectra with distinct minima at 208 and 222 nm (e.g., AspI; Figure 4.3a). 
Dimerization causes a loss of negative ellipticity at 208 nm (e.g., ProI; Figure 4.3a). At 60 
µM, all of the ring-size variants of insulin appear to be dimeric (with CD spectra similar to 
ProI, Figure 4.3a).  
Table 4.1 | Characteristics of insulin variants with different prolyl ring compositions. 
Errors are given as one standard deviation (n ≥ 4). *Quantified by MALDI-MS on proinsulin peptide 
obtained by gluC digestion: 46RGFFYTPKTRRE57. Samples were prepared from combining 5-1L shake 










Lag Time (h) 
KD dimer 
(µM) 
L-Proline -- ProI 90.4 ± 4.2 5.1 ± 1.5 9 μM24 
AzeI ≤100% AzeI 64.5 ± 4.5 4.5 ± 1.5 ~10 μM 
DhpI ≤100% DhpI 72.3 ± 1.3 10.7 ± 1.5 ~10 μM 
ThzI >85% ThzI 83.9 ± 1.3 12.8 ± 1.9 ~10 μM 
PipI 93% PipI 117 ± 19 18.8 ± 3.6 <2 μM 
L-Aspartic acid -- AspI 42.7 ± 4.3 5.3 ± 1.0 >500 μM25 
 
 To obtain estimates for the insulin dimer’s dissociation constant (KD)26, we obtained 
CD spectra at varying concentrations. AzeI, DhpI and ThzI all have a KD of approximately 10 
µM, which is indistinguishable from that of ProI, indicating that slight perturbations to or 
removal of one carbon from the prolyl ring does not affect insulin dimerization. PipI, on the 
other hand, is more dimeric than ProI: at an insulin concentration of 2 µM, ProI is mostly 
monomeric while PipI is still primarily dimeric (KD << 2 µM). 
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Figure 4.3 | Changing ring composition at position B28 affects dimerization and hexamer 
dissociation. 
a, Far UV CD spectra collected on 60 μM insulins in 10 mM phosphate buffer, pH 8.0 at 25°C. b, Insulin 
hexamer dissociation following sequestration of Zn2+ by terpyridine.  Zn2+-(terpy) signal was 
monitored at 334 nm and fitted to a mono-exponential decay. c, Representative fibrillation curves 
for 60 µM insulins (37°C, 960 RPM; n=4). Insulin fibrils were detected by the rise in Thioflavin T (ThT) 
fluorescence that occurs upon binding to fibrillar aggregates. 
 
Decreasing size of prolyl ring at B28 speeds up hexamer dissociation and onset of fibrillation. 
The increasing rate of hexamer dissociation roughly correlates with the decreasing size of the 
prolyl ring. AzeI, which has a 4-membered ring at AzeB28, dissociates the fastest (with a τ½ of 
64.5 ± 4.5 s), followed by DhpI (with a τ½ of 72.3 ± 1.3 s), then ThzI (with a τ½ of 83.4 ± 1.3 s), 
and lastly PipI, which has a 6-membered ring at PipB28, dissociates the slowest (with a τ½ of 
117 ± 19 s). Both AzeI and DhpI display faster hexamer dissociation rates than than ProI (with 
a τ½ of 90.4 ± 4.2 s), and have dimerization constants indistinguishable from that of ProI, 
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further demonstrating that it is possible to decouple the enhancement of hexamer 
dissociation rates (τ½) from destabilization of the insulin dimer (KD).  
Each of the insulin variants were subjected to fibrillation lag time analysis at dilute 
concentrations with the addition of amyloid stain Thioflavin T (ThT). We found that increasing 
size of the prolyl ring size at position B28 of insulin roughly corresponded to a slower 
fibrillation lag time (Figure 4.3c). Compared to ProI and AspI, AzeI is less stable, while DhpI, 
ThzI and PipI are more resistant to fibril formation. To help us understand the mechanisms of 
hexamer dissociation and fibril formation, we solved the crystal structures of AzeI, DhpI, ThzI, 
and PipI in the T2 state and DhpI, ThzI, and PipI in the R6 state.  
Figure 4.4 | Crystal structures of AzeI, DhpI, ThzI, and PipI. 
In top panels (a, b, c, d), insulin variants in the T2 dimer forms. In bottom panels (e, f, g, h), structures 
of insulins in R6 hexamer.  All images highlight the distance between the γ-carbon or its substitution 
group of the prolyl ring at position B28 and its closest neighbors, backbone carbonyl oxygen atoms 
of GlyB20’ and GluB21’, across the dimer interface.  
 
Crystal structures reveal minimal perturbations from changing prolyl ring size.  Solved 
crystal structures for ring-size insulin variants, in comparison with ProI, display overall 
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backbone root-mean-square-deviation (RMSD) values of 0.41 Å (T2-AzeI), 0.34 Å and 0.38 Å 
(T2- and R6-DhpI), 0.31 Å and 0.53 Å (T2- and R6-ThzI), and 0.28 Å and 0.27 Å (T2- and R6-
PipI)27. From the crystal structures (Figure 4.4 and Figure 4.5a), we found that changing the 
size of the prolyl ring did not result in significant perturbations to the proline backbone 
trajectory and largely retains the overall structure of insulin. From the bond angles and 
molecular constraints16,19,28 of Aze, Dhp, Thz and Pip, we found, unsurprisingly, that AzeB28 
and DhpB28 are planar, ThzB28 has an endo conformation, and PipB28 prefers the chair 
conformation. 
Figure 4.5 | Van der Waals contacts at position B28 with neighboring atoms in the T-state. 
a, b, Crystal structures of T2-ProI. Upper left image (a) highlights the distance between the γ-carbon 
or its substitution group of the prolyl ring at position B28 and its closest neighbors, backbone 
carbonyl oxygen atoms of GlyB20’ and GluB21’, across the dimer interface. b-f, Images of T2 insulins 
highlighting vdW contact partners for carbons of the prolyl ring at position B28 for ProI (b), AzeI (c), 




In Chapter 3, we investigated van der Waals (vdW) contacts between residues in the 
dimer interface and interactions with TyrB26, and found that minor perturbations could 
lead to significant biophysical consequences. Based on the biophysical data for hexamer 
dissociation and insulin fibrillation, we hypothesized that increasing ring size, as with Pip, 
provides more accessible surface area across the dimer interface, and decreasing ring size, 
as with Aze and Dhp, provides less accessible surface area for vdW contacts to occur. We 
used crystallography software29 to calculate possible van der Waals contacts at each carbon 
at position B28: α-, β-, and δ-carbons for AzeI, α-, β-, γ-, and δ-carbons for DhpI and ThzI, 
and α-, β-, γ-, δ-, and ε-carbons for PipI (Figure 4.5b-f). PipI, with a significantly slower 
hexamer dissociation rate compared to ProI, and the most resistant to fibril formation (of 
the four ring-size variants), has an extensive network of vdW contacts in the dimer 
interface, and with neighboring residues TyrB26 and ValA3. Compared to PipI, DhpI and ThzI 
have more contacts with neighboring residues TyrB26 and ValA3 than interactions with 
residues GlyB20′ and GluB21′. The network of vdW contacts for ProI, DhpI and ThzI in the T2 
state are qualitatively similar; however, it is difficult to quantify30 the strength of 
hydrophobic interactions in proteins and thus, hard to rationalize the minor atomistic 
differences that account for the changes in biophysical behavior between ProI, DhpI, and 
ThzI. The structure of T2-AzeI is unique (compared to the other ring-size insulin variants) 
because AzeB28 does not form any contacts with TyrB26 (Figure 4.5c). Structural and 
geometric analysis of the interactions between ProB28 and TyrB26 suggests that there 
exists a stabilizing CH/π interaction31-34 between the δ-carbon, and likely also the γ-carbon, 
of ProB28 and the aromatic ring of TyrB26 (Figure 4.6ab), respectively. Aze’s ring is shifted 
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further away from TyrB26, such that the distances, between the hydrogens of AzeB28 and 
the π-component of TyrB26’s aromatic ring, are too large for any vdW overlap and thus, no 
stabilizing CH/π interactions are present in AzeI (Figure 4.6c). The absence of a CH/π 
interaction was also observed in the T2-FypI structure; interestingly, FypI is the only other 
insulin variant we’ve produced that is less stable than ProI based on the results of the ThT 
fibrillation assay. The T2 structures of DhpI, ThzI and PipI shown that CH/π interactions with 
TyrB26 were retained (analyses not shown). 
Figure 4.6 | AzeB28 does not retain any CH-π interactions with TyrB26. 
T2 crystal structures of ProI (a ,b) and AzeI (c). Geometric schematic of CH-π interaction shown in 




 We used the same crystallography software to also compute the network of vdW 
contacts within the R6 structures (Figure 4.7). The results for the R6 structures are nearly 
identical to the network from the T2 structures (Figure 4.5d-f), except for the interaction 
between ValA3 and the α- and β-carbons at positon B28. This interaction is present in both 
monomers for PipI, one of two monomers for ThzI, and is absent in DhpI, suggesting that 
the appearance of this interaction may be a factor in tuning the rate of hexamer 
dissociation, since the rate from slow to fast follows the same order: PipI, ThzI, and DhpI. 
Figure 4.7 | Van der Waals contacts at position B28 with neighboring atoms in the R-state. 
Crystal structures of R6 insulins for ProI (a), DhpI (b), ThzI (c), and PipI (d). Images represent the two 
anti-parallel monomers. vdW contacts are represented by teal lines. 
 
Nature has evolved to use proline as one of twenty cAAs and the resulting protein 
sequence space has encompassed all the functions that are biologically needed; however, 
because protein therapeutics are subjected to synthetic conditions harsher than what has 
been biologically relevant, access to a larger chemical space may become necessary and 
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beneficial. Our results (Chapters 2-4) demonstrate the usefulness of ncAA mutagenesis, an 
approach that fuses the concepts of medicinal chemistry and protein design, and we 
anticipate that this protein engineering strategy will find increasing application in the design 
of antibody-drug conjugates, bispecific antibodies, and other novel protein therapeutics. 
Materials and Methods 
Materials.  All canonical amino acids and (1,3)-thiazolidine-4-carboxylic acid (Thz) were 
purchased from Sigma.  (3,4)-dehydro-L-proline (Dhp) and (S)-azetidine-2-carboxylic acid 
(Aze) was purchased from Bachem Americas.  (S)-piperidine-2-carboxylic acid (Pip) was 
purchased from TCI America under the chemical name L-pipecolic acid.  All solutions and 
buffers were made using double-distilled water (ddH2O).  
Strains and plasmids.  The proinsulin (PI) gene with an N-terminal hexa-histidine tag (6xHIS), 
and flanked by EcoR1 and BamH1 cut sites was ordered as a gBlock (Integrated DNA 
Technologies).  Both the gBlock and vector pQE80L for IPTG-inducible expression were 
digested with EcoRI and BamHI.  Linearized vector pQE80L was dephosphorylated by 
alkaline phosphatase (NEB).  Ligation of the digested PI gene and linearized vector yielded 
plasmid pQE80PI (to produce ProI). To make plasmid pQE80PI-proS (to produce FzpI, FypI 
and dFPI): Genomic DNA was extracted from E. coli strain DH10β using DNeasy Blood and 
Tissue Kit (Qiagen).  Primers (Integrated DNA Technologies) were designed to amplify the E. 
coli proS gene, encoding prolyl-tRNA synthetase, under constitutive control of its 
endogenous promoter, from purified genomic DNA, and to append NheI and NcoI sites.  The 
digested proS gene was then inserted into pQE80PI between transcription termination sites 
by ligation at NheI and NcoI restriction sites. Proline-auxotrophic E. coli strain CAG18515 
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and JT31 was obtained from the Coli Genetic Stock Center at Yale University.  Prototrophic 
E. coli strain BL-21 was used for rich media expression of canonical insulins (ProI, AspI). Site-
directed mutagenesis of pQE80PI at B28 was performed to make plasmid pQE80PI-asp, 
which differs from pQE80PI by three nucleotides that specify a single amino acid mutation 
to aspartic acid. All genes and plasmids were confirmed by DNA sequencing. 
KS32 E. coli strain was made from parent E. coli strain JT31 using λ Red-mediated 
recombination35. JT31 was streaked from glycerol stock disk on an LB plate to obtain single 
colonies; a single colony was inoculated into an overnight culture of 2xYT media before a 
200-fold dilution into the same medium the next morning (cultures were grown at 37°C, 200 
RPM). At OD600 of approximately 0.4, cells were washed extensively in ice cold 10% glycerol 
to remove salts before resuspension in 10% glycerol at an OD600 of ~100. Plasmid pKD46 
was transformed into electrocompetent JT31 cells by electroporation and plated on an LB 
Amp plate at 30°C to obtain single colonies.  A single colony of JT31/pKD46 was made 
inoculated into an overnight culture of 2xYT media before a 200-fold dilution into the same 
medium the next morning (cultures here were grown at 30°C, 200 RPM). At an OD600 
between 0.1 and 0.2, L-arabinose was added to the culture at a concentration of 10mM to 
induce expression of λRED recombinase.  The cells were grown at 30°C until OD600 was 
between 0.4-0.6 before being washed and a final re-suspension with 10% glycerol at 0D600 
of ~100. Ultramers flanking 50 bp upstream and downstream of the proA gene was ordered 
with IDT and used to perform PCR on plasmid pKD3 (flanking regions of proA with a FLP-
CAT-FLP gene in-between); the PCR product was purified uising Zymo DNA concentrator 
spin columns transformed into electro-compentent JT31/pKD46 cells by electroporation 
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(Bio-Rad Electroporator).  After rescuing of cells in SOC media for 1 h, cells were plated at 
1:1 and 1:10 dilutions onto LB-CAM plates, and grown at 42°C to remove pKD46 plasmid.  
Single colonies were re-streaked onto LB-CAM and LB-AMP/CAM; colonies that grew on 
only LB-CAM plates were inoculated into 19aa and 20aa medium to check for auxotrophy.  
Genomic DNA from cells that grew in 20aa, but did not grow in 19aa medium, were purified 
using Qiagen’s DNEasy Blood and Tissue Kit and sequenced to confirm removal of the proA 
gene. Colonies confirmed to have proA gene chromosomally removed were made 
chemically competent to uptake plasmid pCP20 for the removal of the FLP-CAT-FLP gene. 
The final strain KS32 contains a scar in place of proA, which was also confirmed by 
sequencing. 
Protein expression. Plasmids pQE80PI and pQE80PI-asp were transformed into BL21 cells 
and grown on ampicillin-selective agar plates.  A single colony was used to inoculate 5 mL of 
Luria-Bertani (LB) medium and grown overnight; the resulting saturated culture was used to 
inoculate another 1 L of LB medium.  All expression experiments were conducted at 37°C, 
200 RPM in shake flasks (Fernbach 2.8 L flasks, Pyrex®). Each culture was induced with 1 
mM IPTG at mid-exponential phase (OD600 ~0.8).  For incorporation non-canonical prolines, 
pQE80PI-proS was transformed into CAG18515 (for Aze and Pip incorporation) or KS32 cells 
(for Dhp and Thz incorporation), which were grown on ampicillin-selective agar plates. To 
facilitate growth, a single colony was used to inoculate 25 mL of LB medium and the culture 
was grown overnight prior to dilution into 1 L of 1X M9, 20 aa medium (8.5 mM NaCl, 18.7 
mM NH4Cl, 22 mM KH2PO4, 47.8 mM Na2HPO4, 0.1 mM CaCl2, 1 mM MgSO4, 3 mg/L FeSO4, 
1 μg/L of trace metals (Cu2+, Mn2+, Zn2+, MoO42-), 35 mg/L thiamine hydrochloride, 10 mg/L 
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biotin, 20 mM D-glucose, 200 mg/L ampicillin with 50 mg/L of L-amino acids, each).  At an 
appropriate cell density (OD600 ~0.8), the culture was subjected to a medium shift; briefly, 
cells were centrifuged and washed with saline prior to resuspension into 0.8 L of 1.25X M9, 
19 aa (1X M9, 20 aa medium without L-proline).  After cells were further incubated for 30 
min to deplete intracellular proline, 200 mL of 5X additives (1.5 M NaCl, 2.5 mM Aze, Pip, 
Dhp, or Thz) was added to the culture.  After another 15 min of incubation at 37°C to allow 
amino acid uptake prior to induction, IPTG was added to a final concentration of 1 mM.  At 
the end of 2 h, cells were harvested by centrifugation and stored at -80°C until further use.  
Cell lysis and refolding from inclusion bodies.  Cells were thawed on the benchtop for 15 
min prior to resuspension in lysis buffer (B-PER®, 0.5 mg/mL lysozyme, 50 U/mL benzonase 
nuclease).  Cells were gently agitated at RT for 1 h prior to centrifugation (10 000 g, 10 min, 
RT); supernatant was discarded and the pellet was washed thrice: once with wash buffer (2 
M urea, 20 mM Tris, 1% Triton X-100, pH 8.0) and twice with sterile ddH2O; centrifugation 
followed each wash and the supernatant was discarded.  The final washed pellet containing 
inclusion bodies (IBs, ~50% PI) was re-suspended in Ni-NTA binding buffer (8 M urea, 300 
mM NaCl, 50 mM NaH2PO4, pH 8.0) overnight at 4°C or at RT for 2 h, both with gentle 
agitation.  The suspension was centrifuged to remove insoluble debris; the remaining pellet 
was discarded and the supernatant was mixed with pre-equilibrated Ni-NTA resin (Qiagen) 
at RT for 1 h in order to purify PI from the IB fraction.  Unbound proteins in the IB fraction 
were collected in the flow-through (FT), and the resin was washed with Ni-NTA wash buffer 
(8 M urea, 20 mM Tris base, 5 mM imidazole, pH 8.0) and Ni-NTA rinse buffer (8 M urea, 20 
mM Tris base, pH 8.0) prior to stripping PI from the resin with Ni-NTA elution buffer (8 M 
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urea, 20 mM Tris base, pH 3.0).  Fractions (IBs, FT, W, elution) were collected and run under 
reducing conditions on SDS-PAGE (Bis/Tris gels, Novex®); elution fractions containing PI 
were pooled and solution pH was adjusted to 9.6 with 6 N NaOH in preparation for 
oxidative sulfitolysis. Oxidative sulfitolysis was performed at RT for 4 h, with the addition of 
sodium sulfite and sodium tetrathionate (0.2 M Na2SO3, 0.02 M Na2S4O6); the reaction was 
quenched by 10-fold dilution with ddH2O.  To isolate PI from the quenched solution, the pH 
was adjusted to between 3.5 and 4.5 by adding 6 N HCl dropwise; the solution became 
cloudy.  The solution was centrifuged (10 000 g, 10 min, RT) and supernatant discarded.  
The PI pellet was then re-suspended in refolding buffer (0.3 M urea, 50 mM glycine, pH 
10.6) and protein concentration was estimated by the bicinchoninic acid assay (BCA assay, 
Pierce®).  The concentration of PI was adjusted to 0.5 mg/mL.  Refolding was initiated by 
addition of β-mercaptoethanol to a final concentration of 0.5 mM and allowed to proceed 
at 12°C overnight with gentle agitation (New Brunswick® shaker, 100 RPM).  Post-refolding, 
soluble PI was harvested by adjusting the pH of the solution to 4-5 by dropwise addition of 6 
N HCl and by high speed centrifugation to remove insoluble proteins.  The supernatant was 
adjusted to pH 8-8.5 by dropwise addition of 6 N NaOH and dialyzed against fresh PI dialysis 
buffer (7.5 mM sodium phosphate buffer, pH 8.0) at 4°C with five buffer changes to remove 
urea. The retentate (PI in dialysis buffer) was then lyophilized and subsequently stored at -
80°C until further processing.  Typical yields were 25-50 mg PI per L of culture (25-30 mg/L 
for non-canonical PI, 40-50 mg/L for canonical PI expression in rich media) 
Proteolysis and chromatographic (HPLC) purification. The dry PI powder was re-dissolved in 
water to a final concentration of 5 mg/mL PI (final concentration of sodium phosphate 
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buffer is 100 mM, pH 8.0). Trypsin (Sigma-Aldrich) and carboxypeptidase-B (Worthington 
Biochemical) were added to final concentrations of 20 U/mL and 10 U/mL, respectively to 
initiate proteolytic cleavage. The PI/protease solution was incubated at 37°C for 2.5 h; 
proteolysis was quenched by addition of 0.1% trifluoroacetic acid (TFA) and dilute HCl to 
adjust the pH to 4. Matured insulin was purified by reversed phase high-performance liquid 
chromatography (HPLC) on a C18 column using a gradient mobile phase of 0.1% TFA in water 
(solvent, A) and 0.1% TFA in acetonitrile (ACN; solvent, B). Elution was carried from 0% B to 
39% B with a gradient of 0.25% B per minute during peak elution. Fractions were collected 
and lyophilized, and the dry powder was re-suspended into 10 mM sodium phosphate, pH 
8.0. Insulin-containing fractions were verified by matrix-assisted laser 
desorption/ionization-mass spectrometry (MALDI-MS; Voyager MALDI-TOF, Applied 
Biosystems) and SDS-PAGE to ensure identify and purity. Typical yields were 5-10 mg insulin 
per 100 mg PI. Fractions were stored at -80°C in 10 mM phosphate buffer, pH 8.0 until 
further use. 
Verification of ncPro incorporation levels and maturation.  A 30 μL aliquot of PI solution (8 
M urea, 20 mM Tris, pH 8) was subjected to cysteine reduction and alkylation (5 mM DTT, 
55°C, 20 min; 15 mM iodoacetamide, RT, 15 min, dark) prior to 10-fold dilution into 100 mM 
NH4HCO3, pH 8.0 (100 μL final volume).  Peptide digestion was initiated with 0.6 μL of gluC 
stock solution (reconstituted at 0.5 μg/μL with ddH2O, Promega) at 37°C for 2.5 h.  The 
reaction was quenched by adding 10 μL of 5% TFA and immediately subjected to C18 ZipTip 
(Millipore) peptide purification and desalting according to the manufacturer’s protocol.  
Peptides were eluted in 50% ACN, 0.1% TFA; the eluent was then diluted three-fold into 
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matrix solution (saturated α-cyanohydroxycinnamic acid in 50% ACN, 0.1% TFA) and 
analyzed by mass spectrometry (Voyager MALDI-TOF, Applied Biosystems).  Incorporation 
levels were analyzed prior to and after refolding; incorporation percentage was calculated 
by comparing total AUC (area under the curve, arbitrary units) of the non-canonical peak 
with total AUC of its wild-type counterpart (1557 Da and 5808 Da, respectively). Maturation 
of AzeI, PipI, DhpI, or ThzI was analyzed after HPLC purification. TFA (1.6 μL, 5%) was added 
to 15 μL mature insulin solution (10 mM phosphate buffer pH 8.0) and subjected to C18 
ZipTip (Millipore) peptide purification and desalting per the manufacturer’s protocol. 
MALDI-MS conditions described above were used to confirm insulin maturation.   
Circular Dichroism. Spectra were collected in a 1 cm quartz cuvette in 50 mM sodium 
phosphate buffer pH 8.0. Data were collected from 195 nm to 250 nm, with step size of 0.25 
nm and averaging time of 1 s on a Model 410 Aviv Circular Dichroism Spectrophotometer; 
spectra were averaged over 3 repeat scans. A reference buffer spectrum was subtracted 
from the sample spectra for conversion to mean residue ellipticity. Insulin concentrations 
ranged from 3 µM to 250 µM. 
Hexamer Dissociation Assay. Insulins were quantified by both UV absorbance (NanoDrop 
Lite, ThermoFisher) and BCA assay, and normalized to 125 μM insulin prior to dialysis 
against 50 mM Tris/perchlorate, 25 μM zinc sulfate, pH 8.0 overnight at 4°C using a D-tube 
dialyzer (Millipore Corp.) with MWCO of 3.5 kDa.  Aliquots of dialyzed insulin solution were 
mixed with phenol to yield samples of the following composition: 100 μM insulin, 20 μM 
zinc sulfate, 100 mM phenol. Dissociation was initiated by addition of terpyridine (Sigma-
Aldrich) to a final concentration of 0.3 mM from a 0.75 mM stock solution. A Varioskan 
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multimode plate reader (Thermo Scientific) was used to monitor absorbance at 334 nm. 
Kinetic runs were done at least in triplicate, and the data were fit to a mono-exponential 
function using Origin software.  Post assay insulin samples were pooled and sample quality 
was determined by SDS-PAGE. 
Fibrillation Assay.  Insulin samples (60 μM in 10 mM phosphate, pH 8.0) were centrifuged at 
22 000 g for 1 h immediately after addition of thioflavin T (ThT) (EMD Millipore) to a final 
concentration of 1 μM.  Samples were continuously shaken at 960 RPM on a Varioskan 
multimode plate reader at 37°C, and fluorescence readings were recorded every 20 min for 
48 h (excitation 444 nm, emission 485 nm).  Assays were run in quadruplicate, in volumes of 
200 μL in sealed (Perkin-Elmer), black, clear-bottom 96 well plates (Grenier BioOne). 
Crystallographic Studies. Insulin crystals were obtained from sitting drop trays set using a 
Mosquito robot (TTP Labtech). Drops were set by mixing 0.4 μL insulin solution with 0.4 μL 
well solution. Cells were cryoprotected in a mother liquor containing 30% glycerol prior to 
looping and flash freezing in liquid nitrogen. Data were collected at SSRL beamline BL12-2 
using a DECTRIS PILATUS 6M pixel detector. Initial indexing and scaling was performed with 
XDS; for some structures, data were re-scaled in alternative space groups using Aimless36. 
Initial phases were generated by molecular replacement in PHASER with either 3T2A (T2 
structures) or 1EV3 (R6 structures)37. Structure refinement was carried out in Coot and 
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Chapter 5 – Future avenues for insulin 
engineering: Further development of an 











Non-canonical amino acids (ncAAs) have provided great insights to the field of protein 
engineering. However, in many circumstances, the quantity of protein obtained is an 
important factor, and current site-specific and non-bacterial expression systems typically 
result in low protein yields. Here we describe a general and facile screening method for the 
discovery of mutant aminoacyl-tRNA synthetases for the incorporation of new ncAAs using 




Engineering aminoacyl-tRNA synthetases.  Nature is limited in protein sequence space by 
the twenty cAAs and thus, natural evolution1 has evolved proteins to function and have 
properties as far as it is biologically needed. Protein therapeutics, such as insulin, are 
subjected to conditions harsher than the endogenous conditions in which a protein was 
evolved to function in. It can be very possible that certain proteins will never evolve to 
perform a certain function or function optimally under synthetic conditions because there 
has never been any selective pressure to do so. Therefore, in this respect, chemically 
distinct amino acids are beneficial and can lead to new and improved protein functions and 
properties that cannot be (easily) accessed in the canonical protein sequence space2,3. 
Figure 5.1 | Scheme depicting protein translation. 
a, Aminoacylation reaction catalyzed by aminoacyl-tRNA synthetase (aaRS). b, Central dogma of 




The process for protein translation begins with the transcription of DNA into messenger 
RNA (mRNA). The ribosome is then responsible for translating the mRNA into polypeptide, 
which will fold and may undergo post-translational processes to form the final protein. 
Translation involves two key components: the ribosome complex and aminoacylated tRNAs 
(Figure 5.1a). Because the ribosome complex recognizes the RNA portion of the 
aminoacylated tRNA, there is an opportunity to take advantage of the aminoacylation 
reaction to introduce non-canonical amino acids (ncAAs) into the endogenous translation 
process: if an ncAA can be ligated to its cognate tRNA by an aminoacyl-tRNA synthetase 
(aaRS), then the ribosomal complex is typically promiscuous enough to allow for translation 
to proceed. Therefore, it is not a surprise that all current biological approaches for the 
incorporation of ncAA involve aaRS and their cognate tRNAs. It should be noted that the 
ribosomal complex does have elongation factors (e.g. EF-Tu) that must be engineered to 
allow incorporation of certain ncAAs; however, there are only a few such reported cases 
and all involve large, bulky amino acids (e.g. phosphoserine, selenocysteine5). 
Many aaRS have been discovered through high-throughput screening methods for 
the incorporation of non-canonical amino acids (ncAAs). These engineered aaRS have 
allowed for both site- and residue-specific incorporation of ncAA for a variety of protein-
related applications (e.g., cell imaging, conjugation, and engineering protein therapeutics). 
A general screening method to develop aaRS for site-specific incorporation6-8 of ncAAs has 
been reported. However, there is no general screening method for residue-specific 
incorporation of ncAAs; instead, each of the published methods is specific to an aaRS for a 
given amino acid. If it is desired that a ncAA be incorporated residue-specifically and the 
 
 102 
endogenous aaRS cannot accommodate the new amino acid, then the aaRS must be 
adapted. For example, methods for engineering mutant methionyl-tRNA synthetases 
(MetRS) have been developed because of interest in using methionine analogs (ncMet) in 
proteomics experiments (BONCAT). For this purpose, GFP1Met (and related variants) was 
evolved so its fluorescence capability would be insensitive to methionine replacement to 
directly correlate fluorescence with ncMet incorporation. Through fluorescence-activated 
cell sorting9-11, it was then possible to isolate the high fluorescing cells expressing mutant 
MetRS capable of incorporating the desired methionine analog of interest.  
Figure 5.2 | Additional proline analogs for study of insulin biophysics. 
Compound 1: L-proline; Compound 2: (2S,4S)-4-amino-L-proline (Nzp); Compound 3: (2S,4S)-4-
carboxy-L-proline (Czp); Compound 4: (2S,4S)-4-azido-L-proline (Azp); Compound 5: 4-oxo-L-proline 
(Kep); * denotes (2S,4R) variant 
 
Proline. Investigating proline analogs is important because studies in the literature show 
that proline has a critical role in protein folding12, and can influence oligomeric and 
aggregation behavior13,14, act as the gatekeeper allow molecules to flow through ion 
channels or receptors15, and influence other significant biological functions16.  
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 Chapters 2-4 discussed the use of proline analogs to modulate the biophysical 
properties of insulin. One of these analogs, (2S,4S)-4-hydroxy-L-proline (Hzp), when in place 
of the proline residue at position B28, yielded an improved insulin (HzpI), with fast 
dissociation kinetics and enhanced resistance to fibril formation. Crystallographic analysis 
revealed that this may be due to the appearance of a novel hydrogen bond. To build on this 
hypothesis, we sought to utilize a set of analogs with varying polarity and propensity as a 
hydrogen bond donor (Figure 5.2), and conformational preferences17-20. There is no 
literature precedent for non-synthetic methods of incorporation for many ncPros; to this 
end, it would be useful to develop a recombinant expression system that can do so. 
Prolyl-tRNA synthetase. There are two major classes of aaRS: class I synthetases are 
characterized by a Rossman domain in the active site and approach tRNA from the minor 
groove side, while class II synthetases have an antiparallel β-fold in the active site and 
approach tRNA from the major groove side21. Prolyl-tRNA synthetase (ProRS) is considered 
a class II synthetase22. Regardless of categorization, each aaRS serves the larger function of 
charging an amino acid onto the 3’-hydroxyl group of its corresponding tRNA, which 
requires holding the amino acid in proximity to its cognate tRNA and allowing the 
aminoacylation reaction to proceed21. Since each aaRS has evolved to recognize the size, 
shape, and characteristics (e.g., hydrophobicity, charge, polarity) of its cAA23,24, the more a 
ncAA deviates from its analogous cAA in terms of these properties, the less likely it is the 
endogenous aaRS will be able catalyze the aminoacylation reaction. Therefore, by 
engineering the amino acid binding pocket without significantly perturbing any other 
interactions, the aaRS can catalyze the reaction with the same tRNA, but with a ncAA in 
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place of a cAA25. Unfortunately, there is no published crystal structure of E. coli ProRS (Ec 
ProRS), but considering that the twenty cAAs, and tRNAs are conserved across species26, we 
referenced the crystal structure of the Enterococcus faecalis ProRS (Ef ProRS, 46% sequence 
identity to Ec ProRS). The residues that are within close proximity to proline in the binding 
pocket of ProRS represent a good starting point for deciding which residues to mutate to 
switch the synthetase’s selectivity and activity towards other proline analogs (Figure 5.3). 
Mutations at several of these residues, particularly Cys44327, can result in a more 
promiscuous synthetase. 
Figure 5.3 | Prolyl-tRNA synthetase amino acid binding pocket 
On left, Structure of the prokaryotic prolyl-tRNA synthetase (from Enterococcus faecalis ProRS, PDB: 
2J3L) with critical regions labeled and color coded28,29. Inset: Close-up representation of proline 
(shown in teal) in the proline binding pocket. Residue numbers correspond to the analogous residue 
for E. coli ProRS. 
 
 Many studies30-34 on protein evolution suggest that it is difficult to predict beneficial 
mutations that can enhance enzyme activity or protein stability.  In some cases,35,36 the 
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beneficial mutations found were not anywhere near the known active site; therefore, it is 
likely that synthetase engineering, beyond rational design of mutations of the binding 
residues, will require random mutagenesis. A high-throughput screening platform will be 
needed to search through millions of mutants to find a small subset containing beneficial 
mutations for increased incorporation of a particular ncPro.  
Results and Discussion 
Global replacement of proline residues can render full-length GFP non-fluorescent. Previous 
work with GFP1Met and its variants demonstrated success in discovering new mutant MetRS 
for residue-specific incorporation of methionine analogs10,11. There is evidence in the 
literature for residue-specific incorporation of proline analogs (i.e. fluoroprolines37, (3,4)-
dehydro-L-proline38) in GFP without abolishing the protein’s fluorescence capability.  
Figure 5.4 | Residue-specific replacement of proline residues in GFP1Met 
a, Normalized fluorescence of cultures (n = 3) before (PRE) and after induction in minimal medium 
supplemented with 19 amino acids with the addition of either nothing (19aa), (2S,4S)-4-hydroxy-L-
proline (+Hzp) or L-proline (+Pro). b, SDS-PAGE of cell lysates. Green arrow denotes expected location 




We first verified whether GFP fluorescence can be retained with Hzp globally replacing all 
Pro residues; Hzp contains a hydrophilic substituent group, which will provide a larger 
perturbation than the proline analogs previously incorporated into GFP from the literature. 
Preliminary studies on the incorporation of Hzp into GFP1Met yielded a non-fluorescent 
protein (Figure 5.4), indicating fluorescence cannot be correlated with the incorporation of 
proline analogs and GFP1Met cannot be used as to screen for new ProRS for the 
incorporation of proline analogs. One strategy would involve evolving GFP to become 
insensitive to proline replacement (e.g. remove all prolines in GFP or place proline residues 
at permissive locations); this has been done successfully with methionine and tryptophan39. 
However, bioinformatic analysis of fluorescent proteins through comparison of sequence 
homology suggest there are five conserved prolines (J. Cahn and S. Lieblich, personal 
communication, October 31, 2016), indicating that evolving GFP to remove proline residues 
may prove difficult or perhaps even impossible. An alternative approach may be to utilize a 
dual protein-complementation system to minimize the destabilizing effects resulting from 
global replacement of a cAA. In the past decade, many labs have demonstrated the utility of 
split-GFP reporter systems for investigating protein-protein interactions40,41, screening 
protein solubility42, mapping endogenous protein topology43, and imaging cellular 
behavior44,45. We sought to adapt the GFP(1-10)/11 split GFP reporter system into a high-
throughput screening platform for the discovery of mutant prolyl-tRNA synthetases that will 
enable residue-specific incorporation of ncPros into recombinant proteins in E. coli. 
Split-GFP complementation in live bacterial cells. We chose to proceed with the split-GFP 
system to circumvent rendering GFP non-fluorescent. GFP is comprised of two parts, β-
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sheet strands 1-10 and 11 (GFP(1-10) and GFP11), that are non-fluorescent independently 
and need to associate for split-GFP to become fluorescent (Figure 5.5a). Some studies in the 
literature43,46 have appended large, globular proteins to either the N- or C-terminus of 
GFP11 and found that the two parts, GFP(1-10) and GFP11, of split-GFP can complement 
and fluoresce accordingly; therefore, the insertion of prolines to the N-terminus of GFP11 is 
unlikely to interfere with fluorescence output. Our goal is to grow cultures (containing a 
library of ProRS) with GFP(1-10) constitutively expressed before performing a medium shift 
at mid-growth phase to 19aa; after the depletion step (to remove excess intracellular 
proline), we will add the ncPro and induce expression of GFP11 (Figure 5.5b). Cells 
containing mutant synthetases with improved activity towards ncPro will be able to express 
GFP11, which will then associate with the existing pool of GFP(1-10) protein and fluoresce; 
these mutants will then be sorted and sequenced for further validation experiments (Figure 
5.5c). Our initial design was a one-plasmid system, adapted from plasmid pQE80PI-proS 
(from Chapters 2-4), with polycistronic expression of the prolyl-tRNA synthetase and GFP(1-
10), each gene with its own ribosomal binding site (RBS) for independent initiation of 
translation (Figure 5.6a-i). We inserted a proline at the N-terminus of GFP11 to correlate 
proline or proline analog incorporation with GFP11 expression and subsequent fluorescence 
output. Initial expression and fluorescence experiments found that the dynamic range 
between no induction or induction in 19aa (only GFP(1-10) present), and induction in 20aa 
(19aa + Pro) was two-fold (Figure 5.6a-ii); this may be due to the low levels of GFP(1-10) 
that are undetectable with colloidal blue staining (Figure 5.6a-iii). We could not see baseline 
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separation between the distributions of fluorescent and non-fluorescence cell populations 
using a flow cytometer (data not shown). 
Figure 5.5 | Scheme for split-GFP complementation and incorporation. 
a, Homologous fluorescent protein topology map adapted from scheme previously described47. Label 
for β sheet strand 11 (β11) is bolded. b, Scheme for split-GFP complementation and incorporation of 
ncPros. Cells harboring plasmid(s) containing constitutively expressed GFP(1-10) and ProRS are 
grown to mid-exponential phase before being subjected to a medium shift. GFP11 expression is 
induced thereafter in 19aa media with the addition of nothing (19aa), ncPro or Pro (20aa). c, Pictorial 
representation, not actual data, of fluorescence distributions for cell populations subjected to 19aa, 
19aa + ncPro (+ncPro), or 19aa + Pro (20aa) expression conditions. 
 
Selection of constitutive promoters for GFP(1-10) expression. We chose to place GFP(1-10) 
on a separate plasmid under its own promoter48,49 (plasmid from Figure 5.6a-i is near 7 kb in 
length). Selection of promoter for GFP(1-10) expression was done using plasmids shown in 
Figure 5.6b-i with mWasabi (a GFP variant) a reporter protein; p15a is an origin of 
replication that is associated with medium copy numbers. We found that the tac promoter 
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had the best signal-to-noise ratio (Figure 5.6b-ii) when comparing mWasabi fluorescence to 
GFP(1-10) fluorescence . Plasmid ptac_GFP(1-10) was combined with GFP11 constructs 
(Figure 5.6c) and transformed into E. coli for in vivo expression and complementation.  
Figure 5.6 | Split-GFP plasmids for screening mutant prolyl-tRNA synthetases 
a, Single plasmid (ColE1 origin) containing: 1) β11 under inducible lac promoter, 2) GFP(1-10) 
constitutively expressed with 3) gene encoding for ProRS under its endogenous promoter. (ii) 
Fluorescence levels from GFP(1-10)/β11 expression (n=3). (iii) SDS-PAGE of cell lysates; blue arrow 
indicating expected band size of GFP(1-10); absence of band indicates extremely low-level expression. 
b, (i) Plasmids used to select ideal promoter for enhancing GFP(1-10) expression. Promoters derived 
from lac had lacI binding site omitted to maintain constitutive expression. (ii) Fluorescence levels 
comparing signal (Wasabi, positive control) to noise (GFP(1-10), negative control) ratios.  c, (i) GFP11 
variants; E is the elastin sequence (VPGAG)2VPGEG(VPGAG)2. (ii) Fluorescence levels from cells 




Design of GFP11 multi-blocks for enhancing split-GFP fluorescence. The overall GFP11 
constructs followed the design of pQE80PI-proS plasmid constructs from Chapters 2-4; this 
was done with consideration for further insulin (or other therapeutic protein) engineering 
since we had previously obtained good expression yields and high incorporation 
percentages. We first needed to determine that plasmid design and expression conditions 
could facilitate re-assembly of the split GFP fragments and subsequent fluorescence 
readout. We designed three GFP11 constructs: β11, β11 with an N-terminal elastin50-52 
(Eβ11) to aid in expression, linker flexibility, and selectivity for proline incorporation (Eβ11 
polypeptide sequence contains 7 Pro residues compared to 1 Pro residue in β11), and two 
β11s in tandem, with an elastin linker in-between (β11(Eβ11), containing 8 Pro residues in 
total). The latter was designed to increase fluorescence output based on evidence in the 
literature demonstrating that the more β11s in tandem correlates with higher fluorescence 
output44. Co-expression of GFP11 variants and GFP(1-10) with 20 cAAs determined that 
β11(Eβ11) yielded the highest average fluorescence output (Figure 5.6c-ii). 
Plasmids, shown in Figure 5.7a, were transformed in proline-auxotrophic E. coli 
strain CAG18515 and grown in minimal media, supplemented with 20aa until mid-
exponential phase. The cells were then shifted to minimal media, supplemented with 19aa 
for depletion before adding either nothing (19aa), L-pipecolic acid (Pip), 4-oxo-L-proline 
(Kep), (2S,4R)-hydroxy-L-proline (Hyp) or L-proline (20aa), followed by the addition of IPTG 
to induce GFP11 expression. Since the cells were constitutively expressing the wild-type 
synthetase, and based on previous experiments, we expected incorporation percentages to 
be: undetectable for 19aa and Pip, 30% for Keto, 90% for Hyp, and 100% for Pro. We 
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observe this trend in our fluorescence data (Figure 5.7b). In addition, we see good peak 
separation between our negative (19aa) and positive (+Pro) controls and thus, we elected to 
move forward with our screening system. 
Figure 5.7 | Split-GFP system for screening prolyl-tRNA synthetase library. 
a, Plasmids used for screening purposes. b, Fluorescence distribution of cell populations with 
plasmids in (a). Cultures were grown in 20aa (for GFP(1-10) constituitive expression) before medium 
shifted to 19aa, +Pip, +Keto, +Hyp, and +Pro (20aa) for IPTG-induction of GFP11 expression. Flow 
cytometry distributions are normalized to an area of 1 a.u. 
 
Ongoing Work and Future Implications 
Construction and preliminary screening of prolyl-tRNA synthetase libraries. Plasmid 
pQE80(GFP11 inserts)-*proS was designed to be modular. Motifs I, II and III are flanked by 
unique restriction enzyme recognition sites to allow for site-saturation mutagenesis of 
active site residues. In addition, each domain of the synthetase is flanked by unique 
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restriction enzyme recognition sites to allow for focused random mutagenesis of specific 
segments (i.e. the editing domain).  
Figure 5.8 | Scheme for library construction for incorporating proline analogs. 
a, Plasmid design for constructing synthetase libraries. ProRS sections are presented in the close-up 
depication of the proS gene fragment: I, II & III = aminoacylation domain (navy blue); PBL = proline 
binding domain (pink); INS = ProRS editing domain (orange); AC = anti-codon binding loop domain 
(purple). Arrows denote fragments of proS for error-prone library construction. b, Plasmid design for 
constructing either EF-Tu or EF-P libraries. 
 
Site-saturation mutagenesis of residues in the proline binding pocket. Previous work on 
incorporating Nzp using plasmid pQE80PI-proS with mutations at methionine 157 (M157, 
M157D, M157E, M157N and M157Q) found incorporation levels varied between 0 to 
approximately 60%. Using the parent synthetase ProRS (M157Q), which results in an 
incorporation percentage of 60% for Nzp, we constructed the starting library (M157Q x4) by 
randomizing residues 158-161 with NNK codons (N = A, T, C or G; K = C or T) since residues 
D159 and Y161 are in the binding pocket (Figure 5.3).  We choose NNK codons because 2 of 
3 stop codons are eliminated from the possible codons. We obtained 107 transformants 
during both the cloning and expression transformation stages.  
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Figure 5.9 | Cell distributions for naïve library (site-saturation mutagenesis). 
Cultures for flow cytometry were grown to mid-exponential phase for medium shift, followed by a 
brief depletion step and the addition of either nothing (19aa), (2S,4S)-4-amino-L-proline (+Nzp) or 
proline (20aa), prior to IPTG-induction of GFP11 expression. Cell distributions are normalized to an 
area of 1 a.u. a, Fluorescence distribution of cell populations for the parent synthetase (M157Q) and 
naïve library (M157Q x4); 19aa and 20aa samples show as negative (non-fluorescent) and positive 
(fluorescent) controls. b, Fluorescence distribution of cell populations expressing GFP11 in the 
presence of Nzp for the parent synthetase (M157Q), naïve library (M157Q x4), top 0.5% sorted cells 
of the naïve library (M157Q x4-1N). *represents an anomalous peak from the flow cytometer 
 
 The distribution for cells expressing GFP11 (using CAG18515 cells containing the 
plasmids shown in Figure 5.7a) in the presence of Nzp for the naïve library (M157Q x4) is 
less fluorescent than the distribution for cells expressing single mutant ProRS (M157Q).  
This indicates that site-saturation mutagenesis at residues 158-161 (D159 and Y161 are 
represented in Figure 5.3) primarily leads to mutant synthetases that are less active towards 
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Nzp than the parent mutant synthetase (Figure 5.9a; red arrow denotes direction of mean 
fluorescence from parent to naïve library). One possible scenario is that further mutations 
of residues in the binding pocket of ProRS (M157Q) is unlikely to result in enhanced activity 
or selectivity towards Nzp. Nonetheless, we sorted the top 0.5% fluorescing cells from the 
naïve library to isolate library M157Q x4-1N. The mean fluorescence of the distribution for 
cells expressing GFP11 in the presence of Nzp for the sorted library (M157Q x4-1N) is 
slightly shifted to the right (Figure 5.9b; green arrow denotes direction from lower to higher 
fluorescence) compared to the naïve library (M157Q x4); however, this shift is minor and 
suggests the naïve library may not be the ideal starting point. In addition, the loss in mean 
fluorescence, comparable broadness of the fluorescence distribution, and similar number 
and fluorescence of top fluorescing cells between the naïve library and the parent 
synthetase are also indicators that it will be difficult to find a more active synthetase than 
the parent in this naïve library (M157Q x4). 
Error-prone library. The design of the proS gene fragment allows us to further diversify 
prolyl-tRNA synthetase libraries, while avoiding mutations in important consensus domains 
(i.e. anti-codon binding loop; Figure 5.3, colored purple), by focusing mutations in regions 
(i.e. motifs I, II & III, editing domain and PBL) that are more likely to be important for 
switching synthetase selectivity and enhancing aminoacylation activity for proline analogs. 
Based on the results from library M157Q x4, we performed random mutagenesis on the 
gene segment encoding for PBL, editing domain and motif III of the parent synthetase ProRS 
(M157Q) to create the naïve error-prone library (M157Q libA0). Using the same 
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transformation and expression protocols, we subjected M157Q libA0 to GFP11 expression in 
the presence of Nzp (Figure 5.10). 
Figure 5.10 | Cell distributions for naive library (random mutagenesis). 
Cultures for flow cytometry were grown to mid-exponential phase for medium shift, followed by a 
brief depletion step and the addition of either nothing (19aa), (2S,4S)-4-amino-L-proline (+Nzp) or 
proline (20aa), prior to IPTG-induction of GFP11 expression. Cell distributions are normalized to an 
area of 1 a.u. Fluorescence distribution of cell populations for the parent synthetase (M157Q) and 
naïve library (M157Q LibA0); 19aa and 20aa samples show as negative (non-fluorescent) and positive 
(fluorescent) controls. 
 
 The mean fluorescence of the distribution for cells expressing GFP11 in the presence 
of Nzp for the naïve error-prone library (M157Q LibA0) does not display the loss in mean 
fluorescence compared to the parent synthetase (Figure 5.10) that we saw for the M157Q 
x4 library (Figure 5.9).  In particular, at the right tail of the distributions of the cells 
expressing GFP11 in the presence of Nzp, the number of top fluorescing cells for the M157Q 
LibA0 library exceeds that of the parent synthetase; although this result is preliminary, it 
may indicate that it may be possible to find a mutant synthetase with enhanced activity 
and/or selectivity towards Nzp compared to the parent ProRS (M157Q) mutant in the 
M157Q LibA0 library.  
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Library construction for other translational machinery. There exists evidence in the 
literature that the overexpression of elongation factors (EF-Tu53 and EF-P54) is necessary for 
incorporating ncAAs. For some ncAAs, a mutant EF-Tu is required5,55,56 for translation to 
proceed. The role of EF-Tu is essential during the elongation57 step of translation. Our split-
GFP screen can be adapted to find mutant elongation factors by simply inserting an EF-Tu or 
EF-P library downstream of GFP(1-10) in the ptac plasmid (Figure 5.8b). In addition, 
expression levels of EF-Tu (or EF-P) can be optimized by using the same protocols used for 
increasing GFP(1-10) expression (Figure 5.6). 
Continued screening of prolyl-tRNA synthetase libraries. Our interest in incorporating the 
proline analogs in Figure 5.2 is to further engineer insulin. In Chapter 2, we describe a novel 
hydrogen bond formed between the hydroxyl group of HzpB28 and the carbonyl of Glu21′ 
that we believe is responsible for the enhanced hexamer dissociation rates and delayed 
fibrillation behavior of HzpI. For example, an amino group in place of hydroxy at B28 should 
theoretically result in a stronger hydrogen bond with the carbonyl of Glu21′ and if our 
hydrogen bond hypothesis is true, then NzpI may be an insulin variant that has a faster 
hexamer dissociation rate and is more stable than HzpI. Therefore, current work is focusing 
on screening libraries using parent synthetase mutant ProRS (M157Q) to improve Nzp 
incorporation. In parallel, screening for ProRS variants capable of improving Kep and Azp 
incorporation is also underway. Azp provides a chemical handle that allows for chemical 
conjugation via “click chemistry,” which can further expand the repertoire for protein 
engineering through ‘traceless’ Staudinger ligation58,59 reactions. 
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General method for screening aminoacyl-tRNA synthetases.  Due to the length and amino 
acid sequence of β11, it can be postulated that the described screening system can be 
adapted for any cAA analog where the cAA is either not present in β11 or critical for its 
function and re-assembly with GFP(1-10). The necessary steps to adapt this system (for 
other projects involving new ncAAs) would be to clone the relevant synthetase in place of 
proS gene, and then proceed with library construction and subsequent screening.  
 Our goal for implementing a high-throughput screening system is to allow scientists 
to perform medicinal chemistry on proteins as a tool to understand protein behavior on an 
atom-by-atom level and eventually, to improve current or aid in the discovery of new 
therapeutics. 
Materials and Methods 
Materials.  All canonical amino acids, (2S,4S)-4-amino-L-proline, 4-oxo-L-proline, and (2S,4R)-
4-hydroxy-L-proline were purchased from Sigma. A portion of (2S,4S)-4-amino-L-proline was 
also purchased from Toronto Research Chemicals, Limited. (2S,4S)-4-hydroxy-L-proline was 
purchased from Bachem Americas and Pipecolic acid (Pip) was purchased from TCI America.  
All solutions and buffers were made using double-distilled water (ddH2O).  
Plasmid construction.  All gblocks were ordered from Integrated DNA Technologies. 
Restriction enzymes, alkaline phosphatase, and ligase were purchased from New England 
Biolabs. All sequencing was submitted to Laragen for confirmation. All cloning-related 
transformation was done using either Mach1 (Invitrogen) or 10β cells (NEB). Miniprep 
plasmid scale and DNA purification was done using kits purchased from Zymo Research. 
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Large scale purification of plasmid DNA was done using Maxiprep kit purchased from 
Qiagen. Note that a silent mutation was made to proS to insert a Sac1 site (renamed proSs) 
via site-directed mutagenesis for ease of downstream cloning (library insertion). 
Single plasmid. GFP(1-10) gblock with flanking Nhe1 sites and plasmid pQE80MCS-proSs was 
digested with Nhe1 for single-site digestion and ligation to produce plasmid pQE80MCS-
proS_GFP(1-10). GFP11 gblock with flanking BamH1 and Hind3 sites and plasmid pQE80MCS-
proS_GFP(1-10) were digested with BamH1 and Hind3 and purified. Linearized pQE80MCS-
proS_GFP(1-10) was dephosphorylated and purified by gel extraction. Digested GFP11 and 
linearized vector was ligated to produce plasmid pQE80β11-proS_GFP(1-10). 
Double plasmid. GFP(1-10) gblock with flanking BamH1 and Hind3 sites and plasmid 
pKYP680 (obtained from Tirrell Lab cell stocks; pBAD33 plasmid with entire Ara operon 
removed and used as an constitutive expression plasmid) was digested with BamH1 and 
Hind3 and purified. Linearized pKYP680 was dephosphorylated and purified by gel 
extraction.  Digested GFP(1-10) gblock and linearized vector was ligated to produce plasmid 
p15a(J23100)_GFP(1-10) (herein onwards, pKYP680 is renamed p15a(J23100)_Wasabi). 
Promoters OXB20, tac and uv5 were ordered as gblocks with flanking Nsi1 and BamH1, and 
plasmids p15a(J23100)_GFP(1-10) and p15a(J23100)_Wasabi were digested with Nsi1 and 
BamH1 and purified.  Linearized p15a(J23100)_GFP(1-10) and p15a(J23100)_Wasabi were 
also dephosphorylated prior to purification to prevent re-ligation of the vector. Digested 
promoters and linearized vectors were ligated to produce the final constructs: p(promoter)-
_GFP(1-10) and p(promoter)_Wasabi; all eight p15a constructs were confirmed by 
sequencing. All three variations of GFP11 constructs were purchased as gblocks with 
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flanking BamH1 and Hind3 sites and plasmid pQE80MCS-proSs was digested and ligated to 
produce pQE80(GFP11*)-proSs (WT, M157Q and C443G mutants included). 
Library Construction. All libraries were cloned using electro-competent 10β cells. 
Site-saturation mutagenesis. A fragment of the proS gene containing amino acids 120 to 
200, with residues 157-161 randomized through NNK codons, was pieced together by 
sewing PCR using overlap ultramers. Vector backbone, pQE80β11(Eβ11)-proSs was purified 
from 100 mL culture by using Qiagen’s Maxiprep Kit. The PCR library and vector backbone 
was digested with Sac1 and Age1. Linearized vector was dephosphorylated for three times 
longer reaction time to minimize recircularization (and avoid biasing library towards 
truncated products). Ligation reactions used 3 µg of digested backbone with a 3:1 vector-to-
insert molar reaction. To enhance transformation efficiencies, we either purified ligation 
reactions using Zymo DNA concentrator spin columns or used ElectroLigase for 
compatibility for downstream electroporation. Cells transformed by electroporation were 
rescued in Super Optimal Broth with glucose (SOC) medium for 30 minutes at 37°C: a small 
volume was taken for plating and calculation of transformation efficiencies, and the rest 
was inoculated in rich medium (supplemented with ampicillin) overnight for downstream 
plasmid purification. 
Error-prone. To avoid introducing mutations to the promoter and ribosomal binding site 
regions upstream of the start codon, the base pair just upstream of the start codon was 
mutated to introduce a Sph1 cut site (*proSs). Overhang primers containing Sph1 and Nhe1 
sites were used to construct the error-prone library with the GeneMorph II Random 
Mutagenesis kit (Agilent Technologies). Error rate was adjusted by varying the amount of 
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starting template (pQE80β11(Eβ11)-*proSs (M157Q)) and quantified by sequencing. Two 
libraries were constructed (ep-1X and ep-3X) and error rate was determined by sequencing 
to be 9.8 ± 4.1 bp and 3.1± 1.3 bp mutants per proS gene, respectively. 
 A segmented error prone library was constructed using primers: BsrG1-R and Age1-
F.  Two libraries were constructed (LibA and LibB) and error rate was determined by 
sequencing to be 2.5 ± 1.5 bp and 1.5 ± 0.5 bp, respectively. Primers designed for error-
prone PCR are as follows (corresponding the labels in Figure 5.8a): 
• BsrG1-F: 5’-GATACCTTGTGCACGCAGTTCGCTGTACAGTT-3’ 
• Kpn1-F: 5’-TCGGAGTACTTGGTACCCAGCTGGAAGATGTG-3’ 
• Age1-F: 5’-GATAGAACCGGTGTCGGCTTGTACGGCGCGGA-3’ 
• Kpn1-R: 5’-GGTACCAAGTACTCCGAAGCACTGAAAGCCTC-3’ 
• Age1-R: 5’-TGGATTTCCGCGCCGTACAAGCCGACACCGGT-3’ 
• Sac1-R: 5’-TGATTCGTAACGAGCTCAGCTCTTACAAACAG-3’ 
• Sph1-R*: 5’-CTACCTTCCAACTGGAACCGTAACAGCATG-3’ 
Linearized vector was dephosphorylated for three times longer reaction time to minimize 
recircularization (and avoid biasing library towards truncated products). Ligation reactions 
used 3 µg of digested backbone with a 3:1 vector-to-insert molar reaction. To enhance 
transformation efficiencies, we either purified ligation reactions using Zymo DNA 
concentrator spin columns or used ElectroLigase for compatibility for downstream 
electroporation. Cells transformed by electroporation were rescued in Super Optimal Broth 
with glucose (SOC) medium for 30 minutes at 37°C: a small volume was taken for plating 
and calculation of transformation efficiencies, and the rest was inoculated in rich medium 
(supplemented with ampicillin) overnight for downstream plasmid purification.  
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Incorporation of proline analogs into GFP11. Proline-auxotrophic E. coli strain CAG18515 
(CAG) was obtained from the Coli Genetic Stock Center at Yale University and made 
competent. CAG cells containing p15a plasmids were selected by chloramphenicol and 
further made competent to uptake pQE80 plasmids and grown on doubly-selective agar 
plate. Cultures containing either a single mutant or library of synthetases were grown 
overnight prior to 1:40 dilution into 1X M9, 20 aa medium (8.5 mM NaCl, 18.7 mM NH4Cl, 
22 mM KH2PO4, 47.8 mM Na2HPO4, 0.1 mM CaCl2, 1 mM MgSO4, 3 mg/L FeSO4, 1 μg/L of 
trace metals (Cu2+, Mn2+, Zn2+, MoO42-), 35 mg/L thiamine hydrochloride, 10 mg/L biotin, 20 
mM D-glucose, 200 mg/L ampicillin, 50mg/L chloramphenicol with 50 mg/L of L-amino 
acids, each).  All expression experiments were conducted at 37°C, 200 RPM in shake flasks. 
At an appropriate cell density (OD600 ~0.8, growth phase of 3 hours), the culture was 
subjected to a medium shift; briefly, cells were centrifuged and washed with saline thrice 
prior to resuspension into 1.25X M9, 19 aa (1X M9, 20 aa medium without L-proline). After 
cells were further incubated for 30 min to deplete intracellular proline, 200 mL of 5X 
additives (1.5 M NaCl, 2.5 mM ncPro) was added to the culture. After another 15 min of 
incubation at 37°C to allow amino acid uptake prior to induction, IPTG was added to a final 
concentration of 1 mM. At the end of 1 h, cells were either read directly on a microplate 
reader or harvested by centrifugation for pre-processing prior to flow cytometry. Note that 
test co-expressions of GFP(1-10) and GFP11 followed the same protocol except no medium 
shift was performed, instead a 5X solution of NaCl and IPTG (1.5M and 5mM, respectively) 
was added to induce expression of GFP11. 
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Flow Cytometry. 1 h after IPTG induction of GFP11, cells were harvested by centrifugation 
and washed with 10X volume in sterile, cold PBS. Cells were strained using 0.4 µm nylon 
strainer to remove dead cells and other large particulates. FACS screening was performed 
on a MoFlo XDP cell sorter (Beckman Coulter, Brea, CA) using an argon laser (488 nm) and 
530/40 nm bandpass filter. ProRS variants capable of incorporating ncPro were enriched by 
collecting the top 0.5% of cells characterized by the highest levels of fluorescence. Cells 
were sorted into SOC medium (1.5 mL), rescued at 37°C for 1 h, and further diluted into 
antibiotic-selective medium for overnight growth.  A portion of the rescued, sorted cells 
was plated to obtain single colonies for sequencing purposes. Sorted cells not immediately 
used for further sorting were stored at -80°C in 25% glycerol or grown overnight for 
miniprep to obtain plasmid libraries. Naïve libraries were sorted using Purify1 mode and 
sorted cell populations were then subjected to a more stringent sort mode (Single). 
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Proteins have naturally evolved from the 20 canonical amino acids (cAAs) with unique side-
chains that participate in determining the structure of the macromolecule and therefore its 
function as well. The potential to create new proteins becomes near limitless with the 
introduction of non-canonical amino acids (ncAA) whose biorthogonal side chains can be 
synthetically-derived from all of chemical space. 
Much of the focus in this thesis has centered on engineering insulin using ncAAs. Given the 
significance of diabetes within our society today, and predictions based on current trends 
suggesting cases of diabetes will grow even more substantially in the future, insulin is a 
highly relevant and important molecule to thoroughly understand and engineer. 
Compliance among diabetics is a known issue; developing insulins with a faster rate of onset 
is one avenue where there is an unmet need for the treatment of diabetes. We performed 
ncAA mutagenesis at a critical proline residue (but also a residue known to be uninvolved in 
insulin receptor binding and therefore, not critical for biological activity) and show that 
ncAAs can be applied to modulate the biophysical properties of a protein without adversely 
affecting its biological activity. Specifically, based on the side group, the biophysical 
properties of insulin can vary drastically. In the case of the hydroxy-insulins, we found that 
the kinetics of the hexamer dissociation and insulin stability can be improved; this was 
corroborated by structural studies finding evidence for a novel hydrogen bond within the 
insulin dimer interface. In the case of the fluoroinsulins, we find evidence of polar-π 
interactions that may be implicated in modulating insulin stability. Finally, by varying the 
ring-size of the proline surrogate ncAA, the properties of insulin can also be affected on a 
modular scale depending on the number of carbons in the prolyl ring at position B28. 
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Where limitations exist for protein engineering with cAAs, ncAAs may be able to offer a 
novel solution for which biology has never attempted to evolve. However, current methods 
for incorporation of ncAAs into newly synthesized proteins are limiting: not all ncAA can be 
utilized by a host organism’s endogenous translational machinery, large-scale production 
may be difficult due to the practical and logistical demands of a media shift, and 
downstream processing (e.g. production of therapeutic insulin from E. coli requires 
proteolytic cleavage and chromatography purification) may result in a decrease in protein 
yield. The latter two will become more important engineering problems as use of ncAA 
gains in popularity within the scientific community and the demand of biologics increases 
(industrial-scale production to meet market demands). However, developing a system for 
expanding the repertoire of available ncAA possible to incorporate into proteins is of more 
current academic relevance because pilot experiments are generally on the laboratory 
benchtop scale. To this end, the work described in this thesis regarding a screening system 
for ProRS variants is of note. By expanding the possible proline-based amino acids, the 
insulin work described has potentially endless variants. 
The application of ncAA mutagenesis to proteins is a general strategy. As our understanding 
of how to modulate protein properties and how to apply engineered therapeutics to 
combat diseases grows, the engineering strategies described in this work can be applied to 
a wider variety of targets or different problems on a known target. Already, there has been 
work on interferon-β, which is one of the major treatments for multiple sclerosis, where an 
azide-containing ncAA was introduced site-specifically to append a PEG chain to increase 
the drug’s half-life in vivo and minimize the frequency of injections. Other work has focused 
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using the unique chemistry available to ncAAs in the design of potent antibody-drug 
conjugates that can specifically target cancer cells. In the case with insulin, there is great 
interest in the development of hepato-specific and glucose-responsive insulin technologies; 
natural evolution over the past millennia and recent experimental work limited to the cAAs 
has yet to yield any large advances; the ability to access biorthogonal chemistries may be 
necessary to achieve these unmet needs. 
Although it is known that, in general, global replacement of a specific residue in a protein 
often has destabilizing consequences, there is a large body of literature demonstrating that 
laboratory evolution can be used to overcome these limitations. Therefore, it is reasonable 
to remain optimistic about ncAA mutagenesis as a tool for engineering therapeutic proteins. 
The success of engineering insulin with just several ncAAs is indicative that as protein 
engineering research continues to build, more tailored amino acids and effective methods 
for protein engineering will be discovered. 
 
